Comparison	O
of	O
primary	O
sensitization	O
of	O
naive	B-cell_type
human	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
varicella-zoster	O
virus	O
peptides	O
by	O
dendritic	B-cell_type
cells	I-cell_type
in	O
vitro	O
with	O
responses	O
elicited	O
in	O
vivo	O
by	O
varicella	O
vaccination	O
.	O

Dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
are	O
potent	O
APC	B-cell_type
during	O
primary	O
and	O
secondary	O
immune	O
responses	O
.	O

The	O
first	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
human	B-cell_type
DC	I-cell_type
mediate	O
in	O
vitro	O
sensitization	O
of	O
naive	B-cell_type
CD4+	I-cell_type
T	I-cell_type
cells	I-cell_type
to	O
epitopes	B-protein
of	O
the	O
immediate	B-protein
early	I-protein
62	I-protein
(	I-protein
IE62	I-protein
)	I-protein
protein	I-protein
of	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
.	O

The	O
induction	O
of	O
CD4+	B-protein
T	O
cell	O
proliferative	O
responses	O
to	O
eight	O
synthetic	O
peptides	O
representing	O
amino	O
acid	O
sequences	O
of	O
the	O
VZV	B-protein
IE62	I-protein
protein	I-protein
was	O
assessed	O
using	O
T	B-cell_type
cells	I-cell_type
and	O
DC	B-cell_type
from	O
VZV-susceptible	O
donors	O
.	O

The	O
second	O
objective	O
was	O
to	O
compare	O
in	O
vitro	O
responses	O
of	O
naive	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
responses	O
to	O
VZV	O
peptides	O
induced	O
in	O
vivo	O
after	O
immunization	O
with	O
varicella	O
vaccine	O
.	O

T	O
cell	O
proliferation	O
was	O
induced	O
by	O
three	O
peptides	O
,	O
P1	O
,	O
P4	O
,	O
and	O
P7	O
,	O
in	O
71-100	O
%	O
of	O
the	O
donors	O
tested	O
before	O
and	O
after	O
vaccination	O
using	O
DC	B-cell_type
as	O
APC	B-cell_type
.	O

Monocytes	B-cell_type
were	O
effective	O
APC	B-cell_type
for	O
VZV	O
peptides	O
only	O
after	O
immunization	O
.	O

Two	O
peptides	O
,	O
P2	O
and	O
P8	O
,	O
induced	O
naive	O
T	O
cell	O
proliferation	O
less	O
effectively	O
and	O
were	O
also	O
less	O
immunogenic	O
for	O
T	B-cell_type
cells	I-cell_type
from	O
vaccinated	O
or	O
naturally	O
immune	O
donors	O
.	O

T	O
cell	O
recognition	O
of	O
specific	O
peptides	O
was	O
concordant	O
between	O
naive	O
,	O
DC	B-cell_type
-mediated	O
responses	O
,	O
and	O
postvaccine	O
responses	O
using	O
monocytes	B-cell_type
as	O
APC	B-cell_type
in	O
69	O
%	O
of	O
comparisons	O
(	O
p	O
=	O
0.05	O
;	O
chi2	O
)	O
;	O
the	O
predictive	O
value	O
of	O
a	O
positive	O
response	O
to	O
an	O
IE62	O
peptide	O
before	O
immunization	O
for	O
T	O
cell	O
sensitization	O
in	O
vivo	O
was	O
82	O
%	O
.	O

These	O
observations	O
indicate	O
that	O
primary	O
T	O
cell	O
responses	O
detected	O
in	O
vitro	O
using	O
DC	B-cell_type
as	O
APC	B-cell_type
may	O
be	O
useful	O
to	O
characterize	O
the	O
potential	O
immunogenicity	O
of	O
viral	O
protein	O
epitopes	O
in	O
vivo	O
.	O

Accelerating	NULL
Life	NULL
Sciences	NULL
.	NULL

2	NULL
nozzles	NULL
per	NULL
well	NULL
enable	NULL
cell	NULL
Cha	NULL
Check	NULL
out	NULL
how	NULL
Laminar	NULL
Wash	NULL
l	NULL
washing	NULL
by	NULL
creating	NULL
a	NULL
laminar	NULL
T	NULL
‘	NULL
.CU	NULL
RIOX	NULL
systems	NULL
replace	NULL
centrifugation	NULL
completely	NULL
in	NULL
handling	NULL
cells	NULL
See	NULL
How	NULL
It	NULL
Works	NULL
#	NULL
meJournal	NULL
of	NULL
Comparison	NULL
of	NULL
Primary	NULL
Sensitization	NULL
of	NULL
Naive	NULL
4D	NULL
Imnmunolo	NULL
gy	NULL
Human	NULL
T	NULL
Cells	NULL
to	NULL
Varicella-Zoster	NULL
Virus	NULL
Peptides	NULL
by	NULL
Dendritic	NULL
Cells	NULL
In	NULL
Vitro	NULL
with	NULL
This	NULL
information	NULL
i	NULL
Responses	NULL
Elicited	NULL
In	NULL
Vivo	NULL
by	NULL
Varicella	NULL
1s	NULL
information	NULL
1s	NULL
current	NULL
as	NULL
s	NULL
e	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Vaccination	NULL
Darlene	NULL
E.	NULL
Jenkins	NULL
,	NULL
Linda	NULL
L.	NULL
Yasukawa	NULL
,	NULL
Randy	NULL
Bergen	NULL
,	NULL
Claudia	NULL
Benike	NULL
,	NULL
Edgar	NULL
G.	NULL
Engleman	NULL
and	NULL
Ann	NULL
M.	NULL
Arvin	NULL
J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:560-567	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/1/560	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
46	NULL
articles	NULL
,	NULL
24	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/1/560.full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
Comparison	NULL
of	NULL
Primary	NULL
Sensitization	NULL
of	NULL
Naive	NULL
Human	NULL
T	NULL
Cells	NULL
to	NULL
Varicella-Zoster	NULL
Virus	NULL
Peptides	NULL
by	NULL
Dendritic	NULL
Cells	NULL
In	NULL
Vitro	NULL
with	NULL
Responses	NULL
Elicited	NULL
In	NULL
Vivo	NULL
by	NULL
Varicella	NULL
Vaccination	NULL
'	NULL
Darlene	NULL
E.	NULL
Jenkins	NULL
,	NULL
Linda	NULL
L.	NULL
Yasukawa	NULL
,	NULL
Randy	NULL
Bergen	NULL
,	NULL
Claudia	NULL
Benike	NULL
,	NULL
Edgar	NULL
G.	NULL
Engleman	NULL
,	NULL
and	NULL
Ann	NULL
M.	NULL
Arvin	NULL
Dendritic	NULL
cells	NULL
(	NULL
DC	NULL
)	NULL
are	NULL
potent	NULL
APC	NULL
during	NULL
primary	NULL
and	NULL
secondary	NULL
immune	NULL
responses	NULL
.	NULL

The	NULL
first	NULL
objective	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
determine	NULL
whether	NULL
human	NULL
DC	NULL
mediate	NULL
in	NULL
vitro	NULL
sensitization	NULL
of	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
to	NULL
epitopes	NULL
of	NULL
the	NULL
immediate	NULL
early	NULL
62	NULL
(	NULL
IE62	NULL
)	NULL
protein	NULL
of	NULL
varicella	NULL
zoster	NULL
virus	NULL
(	NULL
VZV	NULL
)	NULL
.	NULL

The	NULL
induction	NULL
of	NULL
CD4*	NULL
T	NULL
cell	NULL
proliferative	NULL
responses	NULL
to	NULL
eight	NULL
synthetic	NULL
peptides	NULL
representing	NULL
amino	NULL
acid	NULL
sequences	NULL
of	NULL
the	NULL
VZV	NULL
IE62	NULL
protein	NULL
was	NULL
assessed	NULL
using	NULL
T	NULL
cells	NULL
and	NULL
DC	NULL
from	NULL
VZV-susceptible	NULL
donors	NULL
.	NULL

The	NULL
second	NULL
objective	NULL
was	NULL
to	NULL
compare	NULL
in	NULL
vitro	NULL
responses	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
with	NULL
responses	NULL
to	NULL
VZV	NULL
peptides	NULL
induced	NULL
in	NULL
vivo	NULL
after	NULL
immunization	NULL
with	NULL
varicella	NULL
vaccine	NULL
.	NULL

T	NULL
cell	NULL
proliferation	NULL
was	NULL
induced	NULL
by	NULL
three	NULL
peptides	NULL
,	NULL
P1	NULL
,	NULL
P4	NULL
,	NULL
and	NULL
P7	NULL
,	NULL
in	NULL
71-100	NULL
%	NULL
of	NULL
the	NULL
donors	NULL
tested	NULL
before	NULL
and	NULL
after	NULL
vaccination	NULL
using	NULL
DC	NULL
as	NULL
APC	NULL
.	NULL

Monocytes	NULL
were	NULL
effective	NULL
APC	NULL
for	NULL
VZV	NULL
peptides	NULL
only	NULL
after	NULL
immunization	NULL
.	NULL

Two	NULL
peptides	NULL
,	NULL
P2	NULL
and	NULL
P8	NULL
,	NULL
induced	NULL
naive	NULL
T	NULL
cell	NULL
proliferation	NULL
less	NULL
effectively	NULL
and	NULL
were	NULL
also	NULL
less	NULL
immunogenic	NULL
for	NULL
T	NULL
cells	NULL
from	NULL
vaccinated	NULL
or	NULL
naturally	NULL
immune	NULL
donors	NULL
.	NULL

T	NULL
cell	NULL
recognition	NULL
of	NULL
specific	NULL
peptides	NULL
was	NULL
concordant	NULL
between	NULL
naive	NULL
,	NULL
DC-mediated	NULL
responses	NULL
,	NULL
and	NULL
postvaccine	NULL
responses	NULL
using	NULL
monocytes	NULL
as	NULL
APC	NULL
in	NULL
69	NULL
%	NULL
of	NULL
comparisons	NULL
(	NULL
p	NULL
=	NULL
0.05	NULL
;	NULL
y*	NULL
)	NULL
;	NULL
the	NULL
predictive	NULL
value	NULL
of	NULL
a	NULL
positive	NULL
response	NULL
to	NULL
an	NULL
IE62	NULL
peptide	NULL
before	NULL
immunization	NULL
for	NULL
T	NULL
cell	NULL
sensitization	NULL
in	NULL
vivo	NULL
was	NULL
82	NULL
%	NULL
.	NULL

These	NULL
observations	NULL
indicate	NULL
that	NULL
primary	NULL
T	NULL
cell	NULL
responses	NULL
detected	NULL
in	NULL
vitro	NULL
using	NULL
DC	NULL
as	NULL
APC	NULL
may	NULL
be	NULL
useful	NULL
to	NULL
characterize	NULL
the	NULL
potential	NULL
immunogenicity	NULL
of	NULL
viral	NULL
protein	NULL
epitopes	NULL
in	NULL
vivo	NULL
.	NULL

herpesvirus	NULL
,	NULL
induces	NULL
cellular	NULL
immunity	NULL
that	NULL
protects	NULL
against	NULL
reinfection	NULL
and	NULL
reactivation	NULL
of	NULL
the	NULL
virus	NULL
from	NULL
neuronal	NULL
sites	NULL
of	NULL
latency	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

As	NULL
is	NULL
true	NULL
of	NULL
other	NULL
human	NULL
viral	NULL
pathogens	NULL
,	NULL
current	NULL
understanding	NULL
of	NULL
adaptive	NULL
immunity	NULL
to	NULL
VZV	NULL
is	NULL
based	NULL
largely	NULL
upon	NULL
the	NULL
analysis	NULL
of	NULL
secondary	NULL
T	NULL
cell	NULL
responses	NULL
in	NULL
immune	NULL
individuals	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Memory	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
VZV	NULL
proteins	NULL
has	NULL
been	NULL
characterized	NULL
using	NULL
in	NULL
vitro	NULL
methods	NULL
to	NULL
assess	NULL
CD4	NULL
*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
cytokine	NULL
and	NULL
CTL	NULL
responses	NULL
(	NULL
4-9	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
initial	NULL
sensitization	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
is	NULL
required	NULL
in	NULL
antiviral	NULL
immunity	NULL
,	NULL
it	NULL
has	NULL
been	NULL
difficult	NULL
to	NULL
generate	NULL
a	NULL
primary	NULL
adaptive	NULL
response	NULL
by	NULL
naive	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
capacity	NULL
of	NULL
dendritic	NULL
cells	NULL
(	NULL
DC	NULL
)	NULL
to	NULL
mediate	NULL
the	NULL
sensitization	NULL
of	NULL
unprimed	NULL
T	NULL
cells	NULL
was	NULL
demonstrated	NULL
first	NULL
in	NULL
murine	NULL
systems	NULL
in	NULL
which	NULL
epidermal	NULL
Langerhans	NULL
cells	NULL
and	NULL
splenic	NULL
DC	NULL
were	NULL
found	NULL
to	NULL
elicit	NULL
Ag-specific	NULL
helper	NULL
and	NULL
cytotoxic	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
whereas	NULL
macrophages	NULL
did	NULL
not	NULL
(	NULL
10-16	NULL
)	NULL
.	NULL

It	NULL
is	NULL
now	NULL
possible	NULL
to	NULL
isolate	NULL
human	NULL
DC	NULL
from	NULL
peripheral	NULL
blood	NULL
even	NULL
though	NULL
DC	NULL
represent	NULL
fewer	NULL
than	NULL
0.1-1.0	NULL
%	NULL
of	NULL
circulating	NULL
I	NULL
nfection	NULL
with	NULL
varicella-zoster	NULL
virus	NULL
(	NULL
VZV	NULL
)	NULL
``	NULL
,	NULL
a	NULL
human	NULL
alpha	NULL
Departments	NULL
of	NULL
Pediatrics	NULL
and	NULL
Pathology	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
94305	NULL
Received	NULL
for	NULL
publication	NULL
June	NULL
16	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
September	NULL
8	NULL
,	NULL
1998	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
(	NULL
AT20459	NULL
)	NULL
and	NULL
by	NULL
a	NULL
postdoctoral	NULL
fellowship	NULL
award	NULL
to	NULL
D.E.J	NULL
.	NULL

from	NULL
the	NULL
Varicella-Zoster	NULL
Virus	NULL
Research	NULL
Foundation	NULL
.	NULL

This	NULL
work	NULL
was	NULL
presented	NULL
in	NULL
part	NULL
at	NULL
the	NULL
Third	NULL
International	NULL
Conference	NULL
on	NULL
Varicella	NULL
Zoster	NULL
Virus	NULL
,	NULL
Palm	NULL
Beach	NULL
,	NULL
FL	NULL
,	NULL
March	NULL
9-11	NULL
,	NULL
1997	NULL
.	NULL

2	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Ann	NULL
M.	NULL
Arvin	NULL
,	NULL
G312	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
94305	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
arvinam	NULL
@	NULL
leland.stanford.edu	NULL
3	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
VZV	NULL
,	NULL
varicella	NULL
zoster	NULL
virus	NULL
;	NULL
DC	NULL
,	NULL
dendritic	NULL
cell	NULL
;	NULL
1B62	NULL
,	NULL
immediate	NULL
early	NULL
62	NULL
;	NULL
KLH	NULL
,	NULL
keyhole	NULL
limpit	NULL
hemocyanin	NULL
;	NULL
TT	NULL
,	NULL
tetanus	NULL
toxoid	NULL
;	NULL
SI	NULL
,	NULL
stimulation	NULL
index	NULL
.	NULL

Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
162	NULL
;	NULL
560-567	NULL
.	NULL

PBMC	NULL
.	NULL

The	NULL
functional	NULL
capacity	NULL
of	NULL
DC	NULL
to	NULL
sensitize	NULL
CD4*	NULL
and	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
against	NULL
HIV	NULL
,	NULL
influenza	NULL
A	NULL
,	NULL
and	NULL
other	NULL
nonviral	NULL
Ag	NULL
has	NULL
been	NULL
documented	NULL
(	NULL
17-22	NULL
)	NULL
.	NULL

The	NULL
pathogenesis	NULL
of	NULL
primary	NULL
VZV	NULL
infection	NULL
begins	NULL
with	NULL
the	NULL
inoculation	NULL
of	NULL
mucosal	NULL
epithelial	NULL
cells	NULL
.	NULL

After	NULL
inoculation	NULL
,	NULL
the	NULL
virus	NULL
is	NULL
presumed	NULL
to	NULL
be	NULL
transported	NULL
to	NULL
regional	NULL
lymph	NULL
nodes	NULL
where	NULL
interactions	NULL
of	NULL
viral	NULL
Ags	NULL
with	NULL
host	NULL
immune	NULL
cells	NULL
may	NULL
initiate	NULL
the	NULL
virus-specific	NULL
T	NULL
cell	NULL
response	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
VZV	NULL
transport	NULL
from	NULL
mucosa	NULL
to	NULL
lymph	NULL
nodes	NULL
is	NULL
not	NULL
known	NULL
,	NULL
but	NULL
involvement	NULL
of	NULL
DCs	NULL
is	NULL
a	NULL
possibility	NULL
because	NULL
VZV	NULL
envelope	NULL
glycoproteins	NULL
are	NULL
known	NULL
to	NULL
bind	NULL
mannose	NULL
receptors	NULL
that	NULL
are	NULL
expressed	NULL
in	NULL
abundance	NULL
by	NULL
immature	NULL
or	NULL
nonlymphoid	NULL
DC	NULL
present	NULL
in	NULL
peripheral	NULL
tissues	NULL
(	NULL
10	NULL
,	NULL
19	NULL
,	NULL
23	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Mature	NULL
DC	NULL
,	NULL
which	NULL
localize	NULL
to	NULL
the	NULL
secondary	NULL
lymphoid	NULL
tissues	NULL
in	NULL
vivo	NULL
,	NULL
act	NULL
as	NULL
potent	NULL
APC	NULL
and	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
II	NULL
,	NULL
CD40	NULL
,	NULL
costimulatory	NULL
molecules	NULL
,	NULL
CD80	NULL
and	NULL
CD86	NULL
,	NULL
and	NULL
adhesion	NULL
molecules	NULL
LFA-1	NULL
,	NULL
LFA-3	NULL
,	NULL
and	NULL
ICAM-1	NULL
(	NULL
10	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Abs	NULL
against	NULL
CD86	NULL
,	NULL
HLA-DR	NULL
,	NULL
and	NULL
other	NULL
surface	NULL
molecules	NULL
expressed	NULL
on	NULL
mature	NULL
DC	NULL
inhibit	NULL
the	NULL
sensitization	NULL
of	NULL
naive	NULL
human	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
confirming	NULL
their	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
adaptive	NULL
immunity	NULL
(	NULL
20	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Although	NULL
mature	NULL
DC	NULL
may	NULL
be	NULL
less	NULL
efficient	NULL
at	NULL
capturing	NULL
and	NULL
processing	NULL
whole	NULL
proteins	NULL
than	NULL
immature	NULL
DC	NULL
found	NULL
at	NULL
mucosal	NULL
and	NULL
skin	NULL
sites	NULL
,	NULL
they	NULL
are	NULL
highly	NULL
effective	NULL
in	NULL
presenting	NULL
peptides	NULL
to	NULL
naive	NULL
T	NULL
cells	NULL
(	NULL
26-28	NULL
)	NULL
.	NULL

The	NULL
first	NULL
objective	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
determine	NULL
whether	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
could	NULL
respond	NULL
to	NULL
VZV	NULL
peptides	NULL
presented	NULL
by	NULL
autologous	NULL
DC	NULL
in	NULL
vitro	NULL
.	NULL

Synthetic	NULL
VZV	NULL
peptides	NULL
that	NULL
represent	NULL
amino	NULL
acid	NULL
residues	NULL
of	NULL
the	NULL
immediate	NULL
early	NULL
62	NULL
(	NULL
IE62	NULL
)	NULL
protein	NULL
were	NULL
used	NULL
because	NULL
this	NULL
protein	NULL
is	NULL
recognized	NULL
by	NULL
memory	NULL
T	NULL
cells	NULL
induced	NULL
by	NULL
natural	NULL
infection	NULL
or	NULL
after	NULL
varicella	NULL
immunization	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

The	NULL
IBE62	NULL
protein	NULL
is	NULL
the	NULL
major	NULL
immediate	NULL
early	NULL
transactivating	NULL
protein	NULL
of	NULL
VZV	NULL
;	NULL
it	NULL
initiates	NULL
the	NULL
transcription	NULL
of	NULL
viral	NULL
genes	NULL
required	NULL
to	NULL
produce	NULL
infectious	NULL
virus	NULL
progeny	NULL
and	NULL
is	NULL
the	NULL
predominant	NULL
component	NULL
of	NULL
the	NULL
virion	NULL
tegument	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Because	NULL
it	NULL
is	NULL
present	NULL
in	NULL
the	NULL
tegument	NULL
,	NULL
0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Table	NULL
I	NULL
.	NULL

-	NULL
Synthetic	NULL
peptides	NULL
corresponding	NULL
to	NULL
VZV	NULL
IE62	NULL
sequences	NULL
Peptide	NULL
Amino	NULL
Acid	NULL
Residue	NULL
``	NULL
Amino	NULL
Acid	NULL
Sequence	NULL
``	NULL
1	NULL
18-28	NULL
[	NULL
DTLELMDLLDA	NULL
]	NULL
2	NULL
229-243	NULL
GDGVVLOK	NULL
[	NULL
TQRPAQG	NULL
]	NULL
3	NULL
266-281	NULL
[	NULL
VPGPVEQLYHVLSD	NULL
]	NULL
SV	NULL
4	NULL
519-530	NULL
[	NULL
LGDPARQYRALI	NULL
]	NULL
5	NULL
620-631	NULL
[	NULL
QSLRRAFA	NULL
]	NULL
SMAY	NULL
6	NULL
750-764	NULL
[	NULL
GGFRRIPRGALH	NULL
]	NULL
TFV	NULL
7	NULL
774-1786	NULL
CTP	NULL
[	NULL
ETIARLVDD	NULL
]	NULL
P	NULL
8	NULL
1063-1074	NULL
[	NULL
FDGCKDLARQS	NULL
]	NULL
R	NULL
``	NULL
Amino	NULL
acid	NULL
residues	NULL
based	NULL
on	NULL
VZV	NULL
genome	NULL
sequence	NULL
;	NULL
P8	NULL
was	NULL
designated	NULL
P10	NULL
in	NULL
Bergen	NULL
et	NULL
al	NULL
.	NULL

(	NULL
31	NULL
)	NULL
.	NULL

*	NULL
Underlined	NULL
sequences	NULL
correspond	NULL
to	NULL
the	NULL
algorithm	NULL
from	NULL
Rothbard	NULL
et	NULL
al	NULL
.	NULL

(	NULL
34	NULL
)	NULL
;	NULL
sequences	NULL
within	NULL
brackets	NULL
correspond	NULL
to	NULL
the	NULL
algorithm	NULL
from	NULL
Margalit	NULL
et	NULL
al	NULL
.	NULL

(	NULL
33	NULL
)	NULL
.	NULL

the	NULL
IE62	NULL
protein	NULL
is	NULL
released	NULL
into	NULL
the	NULL
cytoplasm	NULL
of	NULL
the	NULL
infected	NULL
cell	NULL
immediately	NULL
after	NULL
virion	NULL
uncoating	NULL
and	NULL
can	NULL
be	NULL
processed	NULL
for	NULL
Ag	NULL
presentation	NULL
before	NULL
any	NULL
viral	NULL
replication	NULL
has	NULL
occurred	NULL
.	NULL

Memory	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
individuals	NULL
with	NULL
natural	NULL
or	NULL
vaccine-induced	NULL
immunity	NULL
to	NULL
VZV	NULL
recognize	NULL
IE62	NULL
protein	NULL
as	NULL
demonstrated	NULL
by	NULL
proliferation	NULL
and	NULL
production	NULL
of	NULL
IL-2	NULL
and	NULL
IFN-y	NULL
(	NULL
8	NULL
,	NULL
30	NULL
)	NULL
.	NULL

The	NULL
IBEG2	NULL
protein	NULL
is	NULL
also	NULL
a	NULL
target	NULL
of	NULL
VZV-specific	NULL
CTL	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
IE62	NULL
peptides	NULL
that	NULL
we	NULL
used	NULL
to	NULL
investigate	NULL
primary	NULL
in	NULL
vitro	NULL
sensitization	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
by	NULL
DC	NULL
in	NULL
this	NULL
study	NULL
were	NULL
analyzed	NULL
previously	NULL
for	NULL
recognition	NULL
by	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
donors	NULL
with	NULL
naturally	NULL
acquired	NULL
immunity	NULL
to	NULL
VZV	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Assuming	NULL
that	NULL
primary	NULL
sensitization	NULL
could	NULL
be	NULL
demonstrated	NULL
,	NULL
our	NULL
second	NULL
objective	NULL
was	NULL
to	NULL
assess	NULL
how	NULL
the	NULL
pattern	NULL
of	NULL
VZV	NULL
peptide	NULL
recognition	NULL
that	NULL
was	NULL
observed	NULL
using	NULL
T	NULL
cells	NULL
from	NULL
nonimmune	NULL
individuals	NULL
related	NULL
to	NULL
the	NULL
responses	NULL
of	NULL
the	NULL
same	NULL
donors	NULL
after	NULL
VZV	NULL
immunity	NULL
was	NULL
induced	NULL
in	NULL
vivo	NULL
by	NULL
immunization	NULL
with	NULL
the	NULL
varicella	NULL
vaccine	NULL
.	NULL

The	NULL
live	NULL
attenuated	NULL
varicella	NULL
vaccine	NULL
is	NULL
known	NULL
to	NULL
elicit	NULL
protective	NULL
immunity	NULL
to	NULL
VZV	NULL
in	NULL
susceptible	NULL
children	NULL
and	NULL
adults	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Evaluation	NULL
before	NULL
and	NULL
after	NULL
varicella	NULL
vaccination	NULL
provided	NULL
an	NULL
opportunity	NULL
to	NULL
assess	NULL
the	NULL
relevance	NULL
of	NULL
immunogenic	NULL
T	NULL
cell	NULL
epitopes	NULL
,	NULL
defined	NULL
by	NULL
primary	NULL
DC	NULL
presentation	NULL
in	NULL
vitro	NULL
,	NULL
to	NULL
IE6G2	NULL
peptide	NULL
recognition	NULL
detected	NULL
after	NULL
replication	NULL
of	NULL
the	NULL
virus	NULL
in	NULL
the	NULL
host	NULL
.	NULL

Naive	NULL
and	NULL
vaccine-induced	NULL
responses	NULL
were	NULL
also	NULL
compared	NULL
with	NULL
the	NULL
patterns	NULL
of	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
the	NULL
IE6G2	NULL
peptides	NULL
in	NULL
individuals	NULL
with	NULL
naturally	NULL
acquired	NULL
immunity	NULL
to	NULL
VZV	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
VZV	NULL
IE62	NULL
peptides	NULL
and	NULL
other	NULL
antigens	NULL
Synthetic	NULL
IE6G2	NULL
peptides	NULL
were	NULL
made	NULL
to	NULL
correspond	NULL
to	NULL
amino	NULL
acid	NULL
sequences	NULL
predicted	NULL
from	NULL
the	NULL
nucleotide	NULL
sequence	NULL
of	NULL
VZV	NULL
ORF62	NULL
using	NULL
an	NULL
automat-ed-peptide	NULL
synthesizer	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Eight	NULL
peptides	NULL
of	NULL
11-16	NULL
amino	NULL
acid	NULL
residues	NULL
were	NULL
designed	NULL
to	NULL
include	NULL
sequences	NULL
consistent	NULL
with	NULL
algorithms	NULL
for	NULL
potential	NULL
T	NULL
cell	NULL
epitopes	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

After	NULL
synthesis	NULL
,	NULL
the	NULL
crude	NULL
peptides	NULL
were	NULL
purified	NULL
by	NULL
HPLC	NULL
,	NULL
and	NULL
purity	NULL
was	NULL
confirmed	NULL
by	NULL
analytical	NULL
reverse-phase	NULL
HPLC	NULL
and	NULL
amino	NULL
acid	NULL
analysis	NULL
.	NULL

VZV	NULL
IE62	NULL
shares	NULL
some	NULL
functions	NULL
with	NULL
related	NULL
proteins	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
and	NULL
simian	NULL
varicella	NULL
virus	NULL
,	NULL
but	NULL
no	NULL
homologies	NULL
with	NULL
the	NULL
IE6G2	NULL
peptides	NULL
were	NULL
identified	NULL
in	NULL
these	NULL
proteins	NULL
or	NULL
in	NULL
general	NULL
searches	NULL
of	NULL
DNA	NULL
and	NULL
protein	NULL
databases	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

The	NULL
peptides	NULL
were	NULL
designated	NULL
P1-P8	NULL
,	NULL
based	NULL
upon	NULL
their	NULL
order	NULL
in	NULL
the	NULL
IE62	NULL
protein	NULL
sequence	NULL
.	NULL

Whole	NULL
VZV	NULL
Ag	NULL
was	NULL
made	NULL
from	NULL
detergent-solubilized	NULL
VZV-infected	NULL
melanoma	NULL
cells	NULL
;	NULL
an	NULL
uninfected	NULL
cell	NULL
lysate	NULL
was	NULL
used	NULL
as	NULL
control	NULL
Ag	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
whole	NULL
VZV	NULL
Ag	NULL
preparation	NULL
contains	NULL
IE62	NULL
protein	NULL
along	NULL
with	NULL
viral	NULL
glyco-proteins	NULL
,	NULL
enzymes	NULL
,	NULL
and	NULL
other	NULL
regulatory/structural	NULL
proteins	NULL
.	NULL

Other	NULL
antigens	NULL
included	NULL
keyhole	NULL
limpit	NULL
hemocyanin	NULL
(	NULL
KLH	NULL
)	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
,	NULL
purified	NULL
tetanus	NULL
toxoid	NULL
(	NULL
TT	NULL
;	NULL
Michigan	NULL
Public	NULL
Health	NULL
Department	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
)	NULL
and	NULL
phytohemagglutinin	NULL
(	NULL
Difco	NULL
,	NULL
Detroit	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

Identification	NULL
of	NULL
VZV-susceptible	NULL
donors	NULL
and	NULL
immunization	NULL
protocol	NULL
Donors	NULL
who	NULL
were	NULL
not	NULL
immune	NULL
to	NULL
VZV	NULL
were	NULL
identified	NULL
from	NULL
a	NULL
cohort	NULL
of	NULL
adults	NULL
with	NULL
no	NULL
history	NULL
of	NULL
varicella	NULL
by	NULL
demonstrating	NULL
absence	NULL
of	NULL
IgG	NULL
Abs	NULL
to	NULL
561	NULL
VZV	NULL
in	NULL
serum	NULL
,	NULL
as	NULL
tested	NULL
by	NULL
ELISA	NULL
,	NULL
and	NULL
lack	NULL
of	NULL
proliferative	NULL
responses	NULL
when	NULL
PBMC	NULL
cultures	NULL
were	NULL
stimulated	NULL
with	NULL
whole	NULL
VZV	NULL
Ag	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
stimulation	NULL
index	NULL
(	NULL
ST	NULL
)	NULL
is	NULL
calculated	NULL
as	NULL
the	NULL
ratio	NULL
of	NULL
cpm	NULL
in	NULL
whole	NULL
VZV	NULL
Ag-stimulated	NULL
wells	NULL
(	NULL
3.0	NULL
X	NULL
10°	NULL
cells/well	NULL
)	NULL
pulsed	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
,	NULL
compared	NULL
with	NULL
wells	NULL
incubated	NULL
with	NULL
an	NULL
uninfected-cell	NULL
control	NULL
.	NULL

An	NULL
SI	NULL
of	NULL
<	NULL
3.0	NULL
correlates	NULL
with	NULL
susceptiblity	NULL
to	NULL
VZV	NULL
.	NULL

Responses	NULL
of	NULL
12	NULL
donors	NULL
with	NULL
naturally	NULL
acquired	NULL
immunity	NULL
to	NULL
VZV	NULL
,	NULL
defined	NULL
by	NULL
a	NULL
history	NULL
of	NULL
varicella	NULL
IgG	NULL
Abs	NULL
to	NULL
VZV	NULL
and	NULL
SI	NULL
>	NULL
3.0	NULL
,	NULL
were	NULL
also	NULL
analyzed	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
live	NULL
,	NULL
attenuated	NULL
varicella	NULL
vaccine	NULL
used	NULL
in	NULL
this	NULL
study	NULL
was	NULL
produced	NULL
from	NULL
the	NULL
Oka-Merck	NULL
strain	NULL
by	NULL
Merck	NULL
(	NULL
West	NULL
Point	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

Lyophilized	NULL
vaccine	NULL
(	NULL
lots	NULL
0410B	NULL
,	NULL
0773D	NULL
,	NULL
1104D	NULL
,	NULL
1355D	NULL
)	NULL
was	NULL
stored	NULL
at	NULL
-70°C	NULL
before	NULL
use	NULL
.	NULL

The	NULL
vaccine	NULL
was	NULL
administered	NULL
s.c.	NULL
in	NULL
two	NULL
doses	NULL
,	NULL
containing	NULL
>	NULL
3000	NULL
plaque-forming	NULL
units	NULL
of	NULL
infectious	NULL
virus	NULL
per	NULL
dose	NULL
,	NULL
given	NULL
at	NULL
an	NULL
interval	NULL
of	NULL
6-8	NULL
wk	NULL
.	NULL

All	NULL
donors	NULL
had	NULL
received	NULL
TT	NULL
vaccine	NULL
.	NULL

Immunologic	NULL
assays	NULL
were	NULL
done	NULL
before	NULL
varicella	NULL
vaccination	NULL
and	NULL
1-8	NULL
mo	NULL
after	NULL
the	NULL
second	NULL
dose	NULL
of	NULL
vaccine	NULL
.	NULL

Isolation	NULL
of	NULL
DC	NULL
,	NULL
monocytes	NULL
,	NULL
and	NULL
CD4¢	NULL
T	NULL
cells	NULL
DC	NULL
were	NULL
isolated	NULL
from	NULL
human	NULL
peripheral	NULL
blood	NULL
by	NULL
a	NULL
series	NULL
of	NULL
density	NULL
gradient	NULL
centrifugation	NULL
steps	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
PBMCs	NULL
were	NULL
isolated	NULL
from	NULL
buffy	NULL
coats	NULL
by	NULL
Ficoll-Hypaque	NULL
gradient	NULL
and	NULL
then	NULL
frac-tionated	NULL
over	NULL
a	NULL
four-step	NULL
discontinuous	NULL
Percoll	NULL
gradient	NULL
composed	NULL
of	NULL
30	NULL
,	NULL
40	NULL
,	NULL
50	NULL
,	NULL
and	NULL
75	NULL
%	NULL
layers	NULL
.	NULL

The	NULL
fraction	NULL
located	NULL
as	NULL
the	NULL
interface	NULL
of	NULL
the	NULL
40	NULL
and	NULL
50	NULL
%	NULL
layers	NULL
was	NULL
enriched	NULL
further	NULL
by	NULL
adherence	NULL
to	NULL
a	NULL
culture	NULL
flask	NULL
for	NULL
3	NULL
h	NULL
at	NULL
37°C	NULL
and	NULL
served	NULL
as	NULL
a	NULL
source	NULL
of	NULL
monocytes	NULL
for	NULL
experiments	NULL
with	NULL
naive	NULL
T	NULL
cells	NULL
.	NULL

PBLs	NULL
were	NULL
obtained	NULL
from	NULL
the	NULL
interface	NULL
betweeen	NULL
the	NULL
50	NULL
and	NULL
75	NULL
%	NULL
layers	NULL
and	NULL
were	NULL
cultured	NULL
for	NULL
~36	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
complete	NULL
media	NULL
consisting	NULL
of	NULL
RPMI	NULL
1640	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
supplemented	NULL
with	NULL
100	NULL
U/ml	NULL
penicillin	NULL
,	NULL
100	NULL
mg/ml	NULL
!	NULL

streptomycin	NULL
,	NULL
2	NULL
mM	NULL
1-glutamine	NULL
,	NULL
and	NULL
10	NULL
%	NULL
heat-inactivated	NULL
pooled	NULL
human	NULL
serum	NULL
.	NULL

Cultured	NULL
PBLs	NULL
were	NULL
separated	NULL
over	NULL
a	NULL
15	NULL
%	NULL
hypertonic	NULL
metrizamide	NULL
(	NULL
Sigma	NULL
)	NULL
to	NULL
enrich	NULL
for	NULL
DC	NULL
in	NULL
the	NULL
the	NULL
lower	NULL
density	NULL
fraction	NULL
;	NULL
the	NULL
high	NULL
density	NULL
pellet	NULL
was	NULL
used	NULL
for	NULL
isolation	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
DC	NULL
fraction	NULL
was	NULL
incubated	NULL
overnight	NULL
at	NULL
37°C	NULL
and	NULL
a	NULL
second	NULL
metrizamide	NULL
gradient	NULL
(	NULL
14	NULL
%	NULL
)	NULL
was	NULL
used	NULL
to	NULL
enrich	NULL
DC	NULL
further	NULL
.	NULL

DC	NULL
isolations	NULL
resulted	NULL
in	NULL
50-80	NULL
%	NULL
purity	NULL
based	NULL
on	NULL
FACS	NULL
analysis	NULL
(	NULL
high	NULL
MHC	NULL
class	NULL
II	NULL
DR	NULL
,	NULL
CD14-negative	NULL
)	NULL
and	NULL
microscopic	NULL
evalution	NULL
of	NULL
cell	NULL
morphology	NULL
.	NULL

DC	NULL
and	NULL
monocytes	NULL
were	NULL
irradiated	NULL
(	NULL
2400	NULL
rad	NULL
)	NULL
before	NULL
incubation	NULL
with	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
peptides	NULL
to	NULL
decrease	NULL
background	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
the	NULL
first	NULL
high	NULL
density	NULL
metrizamide	NULL
pellet	NULL
with	NULL
CD4*	NULL
magnetic	NULL
mi-crobeads	NULL
(	NULL
Miltenyi	NULL
Biotec	NULL
,	NULL
Auburn	NULL
,	NULL
CA	NULL
)	NULL
using	NULL
a	NULL
positive	NULL
selection	NULL
column	NULL
;	NULL
purity	NULL
of	NULL
92-99	NULL
%	NULL
was	NULL
confirmed	NULL
by	NULL
FACS	NULL
analysis	NULL
.	NULL

Monocytes	NULL
were	NULL
isolated	NULL
from	NULL
PBMC	NULL
preparations	NULL
from	NULL
vaccinated	NULL
donors	NULL
by	NULL
adherance	NULL
;	NULL
these	NULL
preparations	NULL
contained	NULL
>	NULL
78	NULL
%	NULL
monocytes	NULL
by	NULL
FACS	NULL
analysis	NULL
.	NULL

CD4	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
recovered	NULL
from	NULL
nonadherant	NULL
populations	NULL
using	NULL
CD4*	NULL
magnetic	NULL
beads	NULL
.	NULL

CD4*	NULL
T	NULL
cell	NULL
proliferation	NULL
Proliferation	NULL
assays	NULL
were	NULL
conducted	NULL
in	NULL
U-bottom	NULL
96-well	NULL
plates	NULL
using	NULL
50	NULL
ul	NULL
of	NULL
irradiated	NULL
DC	NULL
or	NULL
monocytes	NULL
(	NULL
8.0-10	NULL
X	NULL
10°	NULL
cells/well	NULL
)	NULL
,	NULL
50	NULL
ul	NULL
of	NULL
individual	NULL
IE62	NULL
peptides	NULL
(	NULL
final	NULL
concentrations	NULL
of	NULL
40	NULL
,	NULL
60	NULL
,	NULL
or	NULL
80	NULL
ug/m	NULL
!	NULL

1	NULL
)	NULL
,	NULL
and	NULL
50	NULL
ul	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
3.0	NULL
X	NULL
101.0	NULL
X	NULL
10°	NULL
cells/well	NULL
)	NULL
,	NULL
brought	NULL
to	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
200	NULL
pl/well	NULL
with	NULL
complete	NULL
media	NULL
.	NULL

Control	NULL
wells	NULL
consisted	NULL
of	NULL
DC	NULL
or	NULL
monocytes	NULL
with	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
and	NULL
50	NULL
ul	NULL
KLH	NULL
(	NULL
25	NULL
pg/ml	NULL
!	NULL
)	NULL

or	NULL
50	NULL
ul	NULL
TT	NULL
(	NULL
5	NULL
final	NULL
concentration	NULL
)	NULL
;	NULL
DC	NULL
or	NULL
monocytes	NULL
with	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
no	NULL
peptide	NULL
or	NULL
Ag	NULL
)	NULL
;	NULL
CD4*	NULL
T	NULL
cells	NULL
alone	NULL
;	NULL
or	NULL
CD4*	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
phytohemagglutinin	NULL
.	NULL

KLH	NULL
and	NULL
TT	NULL
were	NULL
used	NULL
as	NULL
control	NULL
Ag	NULL
for	NULL
naive	NULL
and	NULL
memory	NULL
immune	NULL
responses	NULL
,	NULL
respectively	NULL
.	NULL

This	NULL
procedure	NULL
was	NULL
also	NULL
used	NULL
to	NULL
test	NULL
DC	NULL
as	NULL
APC	NULL
after	NULL
immunization	NULL
of	NULL
the	NULL
donors	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
immunized	NULL
donors	NULL
were	NULL
also	NULL
tested	NULL
for	NULL
T	NULL
proliferation	NULL
to	NULL
IE6G2	NULL
peptides	NULL
using	NULL
monocytes	NULL
as	NULL
APC	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
(	NULL
2.4	NULL
X	NULL
10	NULL
``	NULL
/well	NULL
)	NULL
and	NULL
monocytes	NULL
(	NULL
8	NULL
X	NULL
10°/well	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
peptides	NULL
at	NULL
two	NULL
concentrations	NULL
(	NULL
60	NULL
and	NULL
80	NULL
ug/tol	NULL
)	NULL
and	NULL
6-10	NULL
replicates	NULL
per	NULL
concentration	NULL
.	NULL

Naturally	NULL
immune	NULL
or	NULL
susceptible	NULL
subjects	NULL
were	NULL
also	NULL
tested	NULL
as	NULL
described	NULL
previously	NULL
,	NULL
using	NULL
3.0	NULL
X	NULL
10°	NULL
PBMC/well	NULL
,	NULL
with	NULL
22	NULL
replicates	NULL
per	NULL
peptide	NULL
(	NULL
60	NULL
ug/ml	NULL
)	NULL
,	NULL
with	NULL
monocytes	NULL
acting	NULL
as	NULL
APC	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Proliferation	NULL
was	NULL
measured	NULL
by	NULL
incubating	NULL
T	NULL
cell/DC	NULL
,	NULL
T	NULL
cell/monocyte	NULL
,	NULL
or	NULL
PBMC	NULL
cultures	NULL
for	NULL
6	NULL
days	NULL
,	NULL
pulsing	NULL
with	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
,	NULL
and	NULL
harvesting	NULL
after	NULL
18-24	NULL
h.	NULL
Proliferation	NULL
was	NULL
determined	NULL
by	NULL
calculating	NULL
the	NULL
mean	NULL
cpm	NULL
*	NULL
SE	NULL
from	NULL
3	NULL
to	NULL
5	NULL
replicates	NULL
for	NULL
wells	NULL
with	NULL
peptide	NULL
or	NULL
Ag	NULL
and	NULL
from	NULL
6	NULL
to	NULL
10	NULL
replicates	NULL
for	NULL
wells	NULL
measuring	NULL
background	NULL
cpm	NULL
of	NULL
DC	NULL
or	NULL
monocytes	NULL
with	NULL
CD4*	NULL
T	NULL
cells	NULL
alone	NULL
.	NULL

In	NULL
experiments	NULL
using	NULL
DC	NULL
as	NULL
APC	NULL
,	NULL
the	NULL
numbers	NULL
of	NULL
DC	NULL
isolated	NULL
from	NULL
each	NULL
donor	NULL
restricted	NULL
the	NULL
number	NULL
of	NULL
peptides	NULL
that	NULL
could	NULL
be	NULL
tested	NULL
to	NULL
fewer	NULL
than	NULL
8	NULL
in	NULL
some	NULL
cases	NULL
.	NULL

[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
measured	NULL
in	NULL
peptide	NULL
or	NULL
Ag-stimulated	NULL
wells	NULL
and	NULL
control	NULL
wells	NULL
was	NULL
analyzed	NULL
by	NULL
statistical	NULL
comparison	NULL
using	NULL
the	NULL
Student	NULL
's	NULL
?	NULL

test	NULL
for	NULL
two	NULL
means	NULL
.	NULL

The	NULL
donor	NULL
response	NULL
was	NULL
considered	NULL
to	NULL
be	NULL
positive	NULL
to	NULL
the	NULL
peptide	NULL
or	NULL
Ag	NULL
if	NULL
the	NULL
p	NULL
value	NULL
was	NULL
<	NULL
0.05	NULL
using	NULL
a	NULL
two-tail	NULL
analysis	NULL
.	NULL

When	NULL
monocytes	NULL
were	NULL
used	NULL
as	NULL
APC	NULL
in	NULL
the	NULL
assays	NULL
done	NULL
after	NULL
immunization	NULL
,	NULL
positive	NULL
wells	NULL
were	NULL
identified	NULL
as	NULL
those	NULL
with	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
562	NULL
NAIVE	NULL
T	NULL
CELL	NULL
RESPONSES	NULL
IN	NULL
VITRO	NULL
IDENTIFY	NULL
IMMUNOGENIC	NULL
PEPTIDES	NULL
cpm	NULL
>	NULL
mean	NULL
cpm	NULL
for	NULL
all	NULL
wells	NULL
;	NULL
the	NULL
donor	NULL
response	NULL
was	NULL
defined	NULL
as	NULL
significant	NULL
when	NULL
the	NULL
mean	NULL
cpm	NULL
to	NULL
the	NULL
peptide	NULL
was	NULL
<	NULL
0.05	NULL
compared	NULL
with	NULL
the	NULL
mean	NULL
for	NULL
all	NULL
wells	NULL
using	NULL
the	NULL
Student	NULL
's	NULL
1	NULL
test	NULL
for	NULL
two	NULL
means	NULL
.	NULL

The	NULL
positive	NULL
«	NULL
423	NULL
predictive	NULL
value	NULL
was	NULL
calculated	NULL
using	NULL
the	NULL
formula	NULL
,	NULL
a/	NULL
(	NULL
a+b	NULL
)	NULL
,	NULL
in	NULL
which	NULL
``	NULL
a	NULL
``	NULL
is	NULL
the	NULL
number	NULL
of	NULL
donors	NULL
who	NULL
had	NULL
positive	NULL
responses	NULL
before	NULL
and	NULL
after	NULL
immunization	NULL
and	NULL
``	NULL
b	NULL
``	NULL
is	NULL
the	NULL
number	NULL
of	NULL
donors	NULL
with	NULL
a	NULL
positive	NULL
response	NULL
before	NULL
and	NULL
negative	NULL
response	NULL
after	NULL
immunization	NULL
.	NULL

Results	NULL
Optimal	NULL
conditions	NULL
for	NULL
detection	NULL
of	NULL
naive	NULL
T	NULL
cell	NULL
proliferative	NULL
responses	NULL
to	NULL
VZV	NULL
IEG62	NULL
peptides	NULL
presented	NULL
by	NULL
DC	NULL
Preliminary	NULL
titrations	NULL
of	NULL
DC	NULL
showed	NULL
that	NULL
a	NULL
minimum	NULL
of	NULL
8-10	NULL
%	NULL
10°	NULL
DC/well	NULL
was	NULL
necessary	NULL
to	NULL
detect	NULL
proliferation	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
IEG2	NULL
peptides	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
optimal	NULL
DC	NULL
concentration	NULL
identified	NULL
in	NULL
experiments	NULL
using	NULL
HIV	NULL
protein	NULL
or	NULL
peptides	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Because	NULL
the	NULL
number	NULL
of	NULL
DC	NULL
isolated	NULL
from	NULL
peripheral	NULL
blood	NULL
was	NULL
limited	NULL
,	NULL
8.0	NULL
X	NULL
10°	NULL
DC/well	NULL
was	NULL
chosen	NULL
as	NULL
the	NULL
standard	NULL
concentration	NULL
for	NULL
these	NULL
experiments	NULL
.	NULL

Titrations	NULL
of	NULL
peptides	NULL
(	NULL
20-80	NULL
pg/ml	NULL
!	NULL
)	NULL

showed	NULL
that	NULL
T	NULL
cell	NULL
proliferative	NULL
responses	NULL
varied	NULL
depending	NULL
on	NULL
the	NULL
concentration	NULL
of	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Because	NULL
responses	NULL
were	NULL
consistently	NULL
low	NULL
or	NULL
undetectable	NULL
to	NULL
most	NULL
peptides	NULL
tested	NULL
at	NULL
20	NULL
and	NULL
40	NULL
pg/ml	NULL
,	NULL
assays	NULL
were	NULL
done	NULL
using	NULL
peptide	NULL
concentrations	NULL
of	NULL
60	NULL
and	NULL
80	NULL
ug/ml	NULL
;	NULL
P5	NULL
was	NULL
also	NULL
tested	NULL
at	NULL
40	NULL
ug/ml	NULL
because	NULL
responses	NULL
to	NULL
this	NULL
peptide	NULL
were	NULL
detected	NULL
at	NULL
the	NULL
lower	NULL
concentration	NULL
.	NULL

Incubation	NULL
of	NULL
DC	NULL
with	NULL
autologous	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
and	NULL
no	NULL
Ag	NULL
resulted	NULL
in	NULL
nonspecific	NULL
background	NULL
proliferation	NULL
,	NULL
as	NULL
was	NULL
shown	NULL
previously	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Background	NULL
cpm	NULL
with	NULL
IEG2	NULL
peptides	NULL
varied	NULL
with	NULL
the	NULL
number	NULL
of	NULL
CD4*	NULL
T	NULL
cells/well	NULL
;	NULL
a	NULL
range	NULL
of	NULL
3.0	NULL
X	NULL
10	NULL
%	NULL
to	NULL
1.0	NULL
X	NULL
10°	NULL
CD4	NULL
*	NULL
autologous	NULL
T	NULL
cells/well	NULL
was	NULL
optimal	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
responses	NULL
to	NULL
the	NULL
IEG2	NULL
peptides	NULL
.	NULL

Proliferation	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
to	NULL
VZV	NULL
IE62	NULL
peptides	NULL
is	NULL
elicited	NULL
using	NULL
DC	NULL
,	NULL
but	NULL
not	NULL
monocytes	NULL
,	NULL
as	NULL
APC	NULL
The	NULL
primary	NULL
in	NULL
vitro	NULL
proliferative	NULL
response	NULL
to	NULL
IE62	NULL
peptides	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
by	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
obtained	NULL
from	NULL
seven	NULL
VZV-susceptible	NULL
donors	NULL
was	NULL
evaluated	NULL
using	NULL
autologous	NULL
DC	NULL
or	NULL
monocytes	NULL
as	NULL
APC	NULL
.	NULL

Only	NULL
DC	NULL
were	NULL
effective	NULL
as	NULL
APC	NULL
in	NULL
these	NULL
naive	NULL
responses	NULL
.	NULL

In	NULL
a	NULL
representative	NULL
experiment	NULL
,	NULL
three	NULL
of	NULL
the	NULL
four	NULL
IEG2	NULL
peptides	NULL
that	NULL
were	NULL
tested	NULL
induced	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
a	NULL
nonimmune	NULL
donor	NULL
,	NULL
relative	NULL
to	NULL
background	NULL
cpm	NULL
,	NULL
when	NULL
autologous	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
with	NULL
DC	NULL
and	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

Proliferative	NULL
responses	NULL
also	NULL
resulted	NULL
from	NULL
stimulation	NULL
with	NULL
TT	NULL
,	NULL
the	NULL
control	NULL
Ag	NULL
for	NULL
recall	NULL
responses	NULL
,	NULL
and	NULL
with	NULL
KLH	NULL
,	NULL
the	NULL
control	NULL
Ag	NULL
for	NULL
a	NULL
naive	NULL
response	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
no	NULL
in	NULL
vitro	NULL
CD4*	NULL
T	NULL
cell	NULL
response	NULL
to	NULL
IEG2	NULL
peptides	NULL
or	NULL
KLH	NULL
was	NULL
detected	NULL
in	NULL
wells	NULL
when	NULL
monocytes	NULL
were	NULL
used	NULL
as	NULL
APC	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Proliferation	NULL
of	NULL
memory	NULL
T	NULL
cells	NULL
was	NULL
elicited	NULL
by	NULL
TT	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
monocytes	NULL
as	NULL
expected	NULL
,	NULL
because	NULL
all	NULL
donors	NULL
had	NULL
been	NULL
immunized	NULL
with	NULL
tetanus	NULL
vaccine	NULL
.	NULL

The	NULL
in	NULL
vitro	NULL
proliferative	NULL
responses	NULL
of	NULL
seven	NULL
VZV-susceptible	NULL
donors	NULL
to	NULL
the	NULL
panel	NULL
of	NULL
E62	NULL
peptides	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
II	NULL
.	NULL

Presentation	NULL
by	NULL
DC	NULL
elicited	NULL
T	NULL
cell	NULL
proliferation	NULL
to	NULL
a	NULL
minumum	NULL
of	NULL
three	NULL
peptides	NULL
in	NULL
the	NULL
naive	NULL
donors	NULL
,	NULL
and	NULL
one	NULL
donor	NULL
responded	NULL
to	NULL
all	NULL
of	NULL
the	NULL
eight	NULL
peptides	NULL
.	NULL

P4	NULL
was	NULL
the	NULL
most	NULL
immunogenic	NULL
peptide	NULL
,	NULL
inducing	NULL
a	NULL
positive	NULL
response	NULL
in	NULL
all	NULL
of	NULL
the	NULL
donors	NULL
who	NULL
were	NULL
tested	NULL
.	NULL

Other	NULL
peptides	NULL
that	NULL
were	NULL
highly	NULL
immunogenic	NULL
included	NULL
P1	NULL
,	NULL
P5	NULL
,	NULL
and	NULL
P7	NULL
,	NULL
which	NULL
elicited	NULL
T	NULL
cell	NULL
proliferation	NULL
in	NULL
67-83	NULL
%	NULL
of	NULL
the	NULL
naive	NULL
donors	NULL
.	NULL

P3	NULL
,	NULL
P6	NULL
,	NULL
and	NULL
P8	NULL
induced	NULL
responses	NULL
in	NULL
fewer	NULL
donors	NULL
(	NULL
43-60	NULL
%	NULL
)	NULL
whereas	NULL
P2	NULL
presented	NULL
by	NULL
DC	NULL
elicited	NULL
proliferation	NULL
of	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
only	NULL
two	NULL
of	NULL
six	NULL
(	NULL
33	NULL
%	NULL
)	NULL
nonimmune	NULL
subjects	NULL
.	NULL

None	NULL
of	NULL
the	NULL
naive	NULL
donors	NULL
had	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
whole	NULL
VZV	NULL
Ag	NULL
in	NULL
a	NULL
standard	NULL
proliferation	NULL
assay	NULL
using	NULL
PBMC	NULL
in	NULL
which	NULL
monocytes	NULL
act	NULL
as	NULL
APC	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Nonimmune	NULL
donors	NULL
had	NULL
a	NULL
mean	NULL
stimulation	NULL
index	NULL
of	NULL
1.6	NULL
+	NULL
0.40	NULL
SE	NULL
to	NULL
whole	NULL
VZV	NULL
Ag	NULL
.	NULL

50	NULL
&	NULL
o	NULL
%	NULL
a	NULL
3	NULL
9	NULL
ca	NULL
>	NULL
X	NULL
E	NULL
a	NULL
0	NULL
Mono/TC	NULL
-	NULL
KLH	NULL
TT	NULL
P1	NULL
P2	NULL
P4	NULL
P7	NULL
FIGURE	NULL
1	NULL
.	NULL

-	NULL
In	NULL
vitro	NULL
proliferation	NULL
of	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
to	NULL
VZV	NULL
IE62	NULL
peptides	NULL
presented	NULL
by	NULL
autologous	NULL
DC	NULL
or	NULL
monocytes	NULL
.	NULL

The	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
a	NULL
VZV-susceptible	NULL
donor	NULL
in	NULL
response	NULL
to	NULL
VZV	NULL
IE6G2	NULL
peptides	NULL
is	NULL
shown	NULL
for	NULL
a	NULL
representative	NULL
experiment	NULL
comparing	NULL
DC	NULL
(	NULL
4	NULL
)	NULL
and	NULL
monocytes	NULL
(	NULL
B	NULL
)	NULL
as	NULL
APC	NULL
.	NULL

Each	NULL
bar	NULL
shows	NULL
the	NULL
mean	NULL
[	NULL
*HJthymidine	NULL
uptake	NULL
(	NULL
cpm	NULL
X	NULL
10°	NULL
+	NULL
SE	NULL
)	NULL
from	NULL
replicate	NULL
wells	NULL
after	NULL
the	NULL
incubation	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
IE6G2	NULL
peptides	NULL
,	NULL
P1	NULL
,	NULL
P2	NULL
,	NULL
P4	NULL
or	NULL
P7	NULL
,	NULL
and	NULL
APC	NULL
.	NULL

The	NULL
solid	NULL
bars	NULL
indicate	NULL
responses	NULL
using	NULL
IE62	NULL
peptides	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
60	NULL
ug/ml	NULL
,	NULL
and	NULL
the	NULL
shaded	NULL
bars	NULL
show	NULL
responses	NULL
with	NULL
40	NULL
pg/ml	NULL
per	NULL
well	NULL
.	NULL

KLH	NULL
and	NULL
TT	NULL
were	NULL
used	NULL
as	NULL
controls	NULL
for	NULL
naive	NULL
and	NULL
memory	NULL
responses	NULL
,	NULL
respectively	NULL
.	NULL

Background	NULL
mean	NULL
cpm	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
horizontal	NULL
line	NULL
and	NULL
represents	NULL
[	NULL
°HJthymidine	NULL
incorporation	NULL
when	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
APC	NULL
were	NULL
incubated	NULL
without	NULL
peptide	NULL
or	NULL
Ag	NULL
.	NULL

The	NULL
asterisks	NULL
indicate	NULL
a	NULL
positive	NULL
response	NULL
in	NULL
peptide-stimulated	NULL
wells	NULL
compared	NULL
with	NULL
control	NULL
wells	NULL
,	NULL
defined	NULL
as	NULL
p	NULL
<	NULL
0.05	NULL
by	NULL
Student	NULL
's	NULL
f	NULL
test	NULL
for	NULL
2	NULL
means	NULL
.	NULL

Comparison	NULL
of	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
VZV	NULL
IE62	NULL
peptides	NULL
after	NULL
varicella	NULL
immunization	NULL
with	NULL
naive	NULL
responses	NULL
elicited	NULL
by	NULL
DC	NULL
presentation	NULL
The	NULL
induction	NULL
of	NULL
cellular	NULL
immunity	NULL
to	NULL
VZV	NULL
after	NULL
immunization	NULL
of	NULL
VZV-susceptible	NULL
donors	NULL
with	NULL
varicella	NULL
vaccine	NULL
was	NULL
confirmed	NULL
by	NULL
demonstrating	NULL
T	NULL
cell	NULL
proliferation	NULL
in	NULL
PBMC	NULL
cultures	NULL
stimulated	NULL
with	NULL
whole	NULL
VZV	NULL
Ag	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
mean	NULL
SI	NULL
for	NULL
vaccine	NULL
recipients	NULL
tested	NULL
3-4	NULL
wk	NULL
after	NULL
the	NULL
first	NULL
vaccine	NULL
dose	NULL
was	NULL
21.2	NULL
+	NULL
3.70	NULL
SE	NULL
and	NULL
all	NULL
donors	NULL
had	NULL
SI	NULL
>	NULL
3.0	NULL
.	NULL

The	NULL
responses	NULL
were	NULL
maintained	NULL
or	NULL
increased	NULL
when	NULL
evaluated	NULL
3-4	NULL
wk	NULL
after	NULL
the	NULL
second	NULL
dose	NULL
and	NULL
persisted	NULL
at	NULL
6	NULL
mo	NULL
(	NULL
mean	NULL
SI	NULL
:	NULL
18.1	NULL
+	NULL
5.13	NULL
SE	NULL
)	NULL
.	NULL

VZV	NULL
IgG	NULL
Abs	NULL
were	NULL
detected	NULL
by	NULL
ELISA	NULL
after	NULL
immunization	NULL
of	NULL
all	NULL
donors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Table	NULL
II	NULL
.	NULL

-	NULL
Summary	NULL
of	NULL
proliferative	NULL
responses	NULL
to	NULL
VZV	NULL
IEG2	NULL
peptides	NULL
by	NULL
CD4*	NULL
T	NULL
cells	NULL
obtained	NULL
from	NULL
naive	NULL
donors	NULL
before	NULL
varicella	NULL
immunization	NULL
DC	NULL
Pulsed	NULL
with	NULL
Immunogenic	NULL
P1	NULL
P2	NULL
P3	NULL
P4	NULL
P5	NULL
P6	NULL
P7	NULL
P8	NULL
-	NULL
Peptides	NULL
``	NULL
Donor	NULL
+	NULL
+	NULL
8/8	NULL
-	NULL
3/6	NULL
-	NULL
4/8	NULL
+	NULL
5/8	NULL
-	NULL
3/6	NULL
-	NULL
3/7	NULL
+	NULL
+	NULL
5/5	NULL
1	NULL
ick	NULL
w	NULL
bo	NULL
--	NULL
++	NULL
4+	NULL
l	NULL
l	NULL
++	NULL
Io	NULL
+0	NULL
I	NULL
++	NULL
+	NULL
+o	NULL
o++++	NULL
+o	NULL
l	NULL
+	NULL
+	NULL
U	NULL
I	NULL
+1	NULL
+	NULL
+4	NULL
I	NULL
+++	NULL
Donors	NULL
positive	NULL
``	NULL
Ratio	NULL
577	NULL
216	NULL
3/5	NULL
6/6	NULL
416	NULL
3/5	NULL
5/6	NULL
377	NULL
%	NULL
o	NULL
71	NULL
33	NULL
60	NULL
100	NULL
67	NULL
60	NULL
83	NULL
43	NULL
``	NULL
Ratios	NULL
indicate	NULL
positive	NULL
peptide	NULL
responses	NULL
per	NULL
total	NULL
number	NULL
of	NULL
peptides	NULL
tested	NULL
in	NULL
each	NULL
donor	NULL
.	NULL

A	NULL
blank	NULL
indicates	NULL
that	NULL
the	NULL
peptide	NULL
was	NULL
not	NULL
tested	NULL
with	NULL
at	NULL
least	NULL
two	NULL
peptide	NULL
concentrations	NULL
.	NULL

*	NULL
Ratios	NULL
indicate	NULL
positive	NULL
responses	NULL
to	NULL
each	NULL
peptide	NULL
per	NULL
number	NULL
of	NULL
donors	NULL
tested	NULL
.	NULL

CD4	NULL
*	NULL
T	NULL
cell	NULL
proliferative	NULL
responses	NULL
to	NULL
IEG2	NULL
peptides	NULL
were	NULL
evaluated	NULL
in	NULL
five	NULL
donors	NULL
after	NULL
varicella	NULL
immunization	NULL
and	NULL
compared	NULL
with	NULL
the	NULL
responses	NULL
of	NULL
their	NULL
naive	NULL
T	NULL
cells	NULL
to	NULL
these	NULL
peptides	NULL
in	NULL
vitro	NULL
.	NULL

Proliferation	NULL
to	NULL
IE62	NULL
peptides	NULL
by	NULL
T	NULL
cells	NULL
from	NULL
donors	NULL
who	NULL
were	NULL
tested	NULL
after	NULL
immunization	NULL
was	NULL
assessed	NULL
in	NULL
cultures	NULL
using	NULL
either	NULL
DC	NULL
or	NULL
monocytes	NULL
as	NULL
APC	NULL
.	NULL

Examples	NULL
of	NULL
the	NULL
responses	NULL
of	NULL
two	NULL
donors	NULL
who	NULL
were	NULL
evaluated	NULL
for	NULL
T	NULL
cell	NULL
proliferation	NULL
to	NULL
IE62	NULL
peptides	NULL
before	NULL
and	NULL
after	NULL
vaccination	NULL
are	NULL
illustrated	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Donor	NULL
1	NULL
responded	NULL
to	NULL
all	NULL
peptides	NULL
that	NULL
were	NULL
tested	NULL
before	NULL
and	NULL
after	NULL
immunization	NULL
using	NULL
DC	NULL
as	NULL
APC	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
panels	NULL
1A	NULL
and	NULL
1B	NULL
)	NULL
and	NULL
to	NULL
seven	NULL
of	NULL
eight	NULL
peptides	NULL
using	NULL
monocytes	NULL
as	NULL
APC	NULL
after	NULL
immunization	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
panel	NULL
1C	NULL
)	NULL
.	NULL

Donor	NULL
3	NULL
had	NULL
naive	NULL
and	NULL
memory	NULL
T	NULL
cells	NULL
that	NULL
responded	NULL
to	NULL
P4	NULL
and	NULL
P7	NULL
using	NULL
DC	NULL
as	NULL
APC	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
panels	NULL
3A	NULL
and	NULL
3B	NULL
)	NULL
.	NULL

Responses	NULL
to	NULL
P2	NULL
,	NULL
P3	NULL
,	NULL
P5	NULL
,	NULL
P6	NULL
,	NULL
and	NULL
P8	NULL
,	NULL
as	NULL
well	NULL
as	NULL
to	NULL
P4	NULL
and	NULL
P7	NULL
,	NULL
were	NULL
detected	NULL
after	NULL
vaccination	NULL
using	NULL
monocytes	NULL
as	NULL
APC	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
panel	NULL
3C	NULL
)	NULL
.	NULL

80	NULL
B	NULL
Pre-vaccine	NULL
R	NULL
&	NULL
vio2	NULL
eo	NULL
H	NULL
veno	NULL
v2D21	NULL
P	NULL
2	NULL
O	NULL
em	NULL
$	NULL
A	NULL
¥	NULL
=	NULL
F	NULL
w	NULL
40	NULL
-	NULL
3	NULL
7	NULL
2	NULL
7	NULL
7	NULL
7	NULL
7	NULL
7	NULL
20	NULL
-	NULL
¥	NULL
$	NULL
$	NULL
2	NULL
{	NULL
7	NULL
7	NULL
2	NULL
7	NULL
0	NULL
#	NULL
Donor	NULL
1	NULL
Donor	NULL
2	NULL
Donor	NULL
3	NULL
Donor	NULL
4	NULL
Donor	NULL
5	NULL
4	NULL
FIGURE	NULL
2	NULL
.	NULL

-	NULL
Confirmation	NULL
of	NULL
cellular	NULL
immunity	NULL
to	NULL
VZV	NULL
after	NULL
immunization	NULL
with	NULL
the	NULL
varicella	NULL
vaccine	NULL
.	NULL

Five	NULL
VZV	NULL
susceptible	NULL
donors	NULL
were	NULL
tested	NULL
for	NULL
proliferation	NULL
responses	NULL
to	NULL
whole	NULL
VZV	NULL
Ag	NULL
in	NULL
PBMC	NULL
cultures	NULL
.	NULL

Donors	NULL
were	NULL
tested	NULL
before	NULL
immunization	NULL
(	NULL
prevaccine	NULL
)	NULL
,	NULL
21	NULL
days	NULL
after	NULL
the	NULL
first	NULL
dose	NULL
(	NULL
V1D21	NULL
)	NULL
,	NULL
just	NULL
before	NULL
the	NULL
second	NULL
dose	NULL
(	NULL
V2D0	NULL
)	NULL
,	NULL
21	NULL
days	NULL
after	NULL
the	NULL
second	NULL
dose	NULL
(	NULL
V2D21	NULL
)	NULL
and	NULL
6	NULL
mo	NULL
(	NULL
6	NULL
M	NULL
)	NULL
after	NULL
immunization	NULL
.	NULL

The	NULL
SI	NULL
was	NULL
calculated	NULL
as	NULL
the	NULL
ratio	NULL
of	NULL
mean	NULL
cpm	NULL
(	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
)	NULL
in	NULL
wells	NULL
incubated	NULL
with	NULL
whole	NULL
VZV	NULL
Ag	NULL
compared	NULL
with	NULL
wells	NULL
containing	NULL
uninfected-cell	NULL
control	NULL
.	NULL

563	NULL
A	NULL
summary	NULL
of	NULL
the	NULL
responses	NULL
of	NULL
all	NULL
five	NULL
donors	NULL
who	NULL
were	NULL
tested	NULL
before	NULL
and	NULL
after	NULL
vaccination	NULL
is	NULL
given	NULL
in	NULL
Table	NULL
III	NULL
.	NULL

Postvacceination	NULL
,	NULL
all	NULL
donors	NULL
had	NULL
memory	NULL
T	NULL
cell	NULL
proliferation	NULL
to	NULL
a	NULL
minimum	NULL
of	NULL
three	NULL
peptides	NULL
.	NULL

As	NULL
was	NULL
observed	NULL
in	NULL
experiments	NULL
using	NULL
naive	NULL
T	NULL
cells	NULL
,	NULL
P4	NULL
was	NULL
the	NULL
most	NULL
immunogenic	NULL
IE62	NULL
peptide	NULL
after	NULL
varicella	NULL
immunization	NULL
using	NULL
monocytes	NULL
or	NULL
DC	NULL
as	NULL
APC	NULL
;	NULL
positive	NULL
responses	NULL
were	NULL
detected	NULL
in	NULL
all	NULL
five	NULL
donors	NULL
.	NULL

When	NULL
monocytes	NULL
were	NULL
used	NULL
as	NULL
APC	NULL
to	NULL
test	NULL
IE62	NULL
peptide	NULL
recognition	NULL
after	NULL
immunization	NULL
,	NULL
P1	NULL
,	NULL
P4	NULL
,	NULL
and	NULL
P6	NULL
induced	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
80	NULL
to	NULL
100	NULL
%	NULL
of	NULL
donors	NULL
whereas	NULL
P2	NULL
and	NULL
P8	NULL
were	NULL
less	NULL
immunogenic	NULL
(	NULL
40-60	NULL
%	NULL
)	NULL
.	NULL

Using	NULL
DC	NULL
as	NULL
APC	NULL
,	NULL
P1	NULL
and	NULL
P7	NULL
were	NULL
immunogenic	NULL
for	NULL
most	NULL
donors	NULL
before	NULL
and	NULL
after	NULL
immunization	NULL
whereas	NULL
P2	NULL
and	NULL
P8	NULL
were	NULL
poor	NULL
stimulators	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
both	NULL
naive	NULL
and	NULL
immune	NULL
donors	NULL
;	NULL
P6	NULL
was	NULL
recognized	NULL
by	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
80	NULL
%	NULL
donors	NULL
after	NULL
vaccination	NULL
when	NULL
peptides	NULL
were	NULL
presented	NULL
by	NULL
DC	NULL
,	NULL
compared	NULL
with	NULL
60	NULL
%	NULL
in	NULL
susceptible	NULL
donors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
pattern	NULL
of	NULL
IE62	NULL
peptides	NULL
recognized	NULL
by	NULL
naive	NULL
and	NULL
memory	NULL
T	NULL
cells	NULL
from	NULL
each	NULL
donor	NULL
was	NULL
compared	NULL
by	NULL
statistical	NULL
analysis	NULL
(	NULL
Table	NULL
III	NULL
)	NULL
.	NULL

Using	NULL
monocytes	NULL
as	NULL
APC	NULL
,	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
specific	NULL
peptides	NULL
was	NULL
concordant	NULL
between	NULL
naive	NULL
DC-mediated	NULL
responses	NULL
and	NULL
postvaccine	NULL
responses	NULL
in	NULL
69	NULL
%	NULL
of	NULL
assays	NULL
(	NULL
p	NULL
=	NULL
0.05	NULL
;	NULL
y	NULL
``	NULL
)	NULL
.	NULL

In	NULL
19	NULL
of	NULL
36	NULL
comparisons	NULL
,	NULL
naive	NULL
and	NULL
memory	NULL
responses	NULL
were	NULL
both	NULL
positive	NULL
and	NULL
in	NULL
6	NULL
comparisons	NULL
,	NULL
the	NULL
peptide	NULL
was	NULL
not	NULL
immunogenic	NULL
either	NULL
before	NULL
or	NULL
after	NULL
varicella	NULL
immunization	NULL
.	NULL

Discordant	NULL
responses	NULL
that	NULL
were	NULL
negative	NULL
in	NULL
naive	NULL
T	NULL
cell	NULL
cultures	NULL
and	NULL
positive	NULL
after	NULL
in	NULL
vivo	NULL
sensitization	NULL
occurred	NULL
in	NULL
7	NULL
of	NULL
36	NULL
comparisons	NULL
(	NULL
19	NULL
%	NULL
)	NULL
,	NULL
and	NULL
in	NULL
4	NULL
cases	NULL
(	NULL
11	NULL
%	NULL
)	NULL
naive	NULL
T	NULL
cells	NULL
responded	NULL
but	NULL
memory	NULL
T	NULL
cells	NULL
stimulated	NULL
by	NULL
the	NULL
IE6G2	NULL
peptide	NULL
did	NULL
not	NULL
.	NULL

The	NULL
positive	NULL
predictive	NULL
value	NULL
of	NULL
peptide	NULL
recognition	NULL
by	NULL
naive	NULL
T	NULL
cells	NULL
detected	NULL
before	NULL
vaccination	NULL
relative	NULL
to	NULL
responses	NULL
to	NULL
the	NULL
same	NULL
peptide	NULL
after	NULL
in	NULL
vivo	NULL
sensitization	NULL
by	NULL
varicella	NULL
vaccine	NULL
was	NULL
82	NULL
%	NULL
using	NULL
monocytes	NULL
as	NULL
APC	NULL
for	NULL
memory	NULL
T	NULL
cells	NULL
.	NULL

When	NULL
DC	NULL
were	NULL
used	NULL
as	NULL
APC	NULL
both	NULL
before	NULL
and	NULL
after	NULL
vaccina-tion	NULL
,	NULL
a	NULL
concordance	NULL
of	NULL
the	NULL
proliferative	NULL
responses	NULL
to	NULL
specific	NULL
peptides	NULL
was	NULL
observed	NULL
in	NULL
25	NULL
of	NULL
36	NULL
comparisons	NULL
(	NULL
p	NULL
=	NULL
0.03	NULL
;	NULL
y	NULL
``	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
VZV	NULL
IE62	NULL
peptide	NULL
responses	NULL
in	NULL
donors	NULL
with	NULL
natural	NULL
immunity	NULL
,	NULL
VZV-susceptible	NULL
donors	NULL
,	NULL
and	NULL
donors	NULL
immunized	NULL
with	NULL
varicella	NULL
vaccine	NULL
A	NULL
comparison	NULL
of	NULL
the	NULL
percentage	NULL
of	NULL
naive	NULL
,	NULL
immunized	NULL
,	NULL
and	NULL
naturally	NULL
immune	NULL
donors	NULL
who	NULL
had	NULL
proliferative	NULL
responses	NULL
to	NULL
each	NULL
of	NULL
the	NULL
eight	NULL
IEG2	NULL
peptides	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

More	NULL
than	NULL
70	NULL
%	NULL
of	NULL
donors	NULL
in	NULL
all	NULL
groups	NULL
had	NULL
T	NULL
cell	NULL
proliferation	NULL
to	NULL
P1	NULL
and	NULL
P4	NULL
.	NULL

A	NULL
memory	NULL
T	NULL
cell	NULL
proliferation	NULL
response	NULL
to	NULL
the	NULL
IEG2	NULL
peptides	NULL
,	NULL
P1	NULL
,	NULL
P3	NULL
,	NULL
P4	NULL
,	NULL
P5	NULL
,	NULL
and	NULL
P6	NULL
,	NULL
was	NULL
detected	NULL
previously	NULL
in	NULL
75-87	NULL
%	NULL
of	NULL
12	NULL
donors	NULL
with	NULL
naturally	NULL
acquired	NULL
immunity	NULL
to	NULL
VZV	NULL
using	NULL
unfractionated	NULL
PBMC	NULL
cultures	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Fewer	NULL
donors	NULL
responded	NULL
to	NULL
P2	NULL
(	NULL
42	NULL
%	NULL
)	NULL
,	NULL
P7	NULL
(	NULL
50	NULL
%	NULL
)	NULL
,	NULL
and	NULL
P8	NULL
(	NULL
67	NULL
%	NULL
)	NULL
.	NULL

The	NULL
mean	NULL
cpm	NULL
in	NULL
proliferation	NULL
assays	NULL
was	NULL
highest	NULL
with	NULL
P1	NULL
(	NULL
2.6	NULL
x	NULL
10°	NULL
+	NULL
430	NULL
SE	NULL
)	NULL
and	NULL
P4	NULL
(	NULL
2.3	NULL
x	NULL
10°	NULL
+	NULL
491	NULL
SE	NULL
)	NULL
and	NULL
lowest	NULL
with	NULL
P8	NULL
(	NULL
1.6	NULL
X	NULL
10°	NULL
+	NULL
718	NULL
SE	NULL
)	NULL
among	NULL
donors	NULL
who	NULL
responded	NULL
to	NULL
the	NULL
peptide	NULL
.	NULL

Discussion	NULL
These	NULL
experiments	NULL
demonstrate	NULL
that	NULL
a	NULL
naive	NULL
T	NULL
cell	NULL
response	NULL
can	NULL
be	NULL
induced	NULL
in	NULL
vitro	NULL
by	NULL
peptides	NULL
corresponding	NULL
to	NULL
residues	NULL
of	NULL
the	NULL
E62	NULL
protein	NULL
,	NULL
an	NULL
immunogenic	NULL
protein	NULL
of	NULL
VZV	NULL
,	NULL
when	NULL
Ag	NULL
presentation	NULL
is	NULL
mediated	NULL
by	NULL
autologous	NULL
DC	NULL
.	NULL

Our	NULL
findings	NULL
are	NULL
consistent	NULL
with	NULL
the	NULL
observations	NULL
that	NULL
human	NULL
DC	NULL
are	NULL
required	NULL
to	NULL
stimulate	NULL
primary	NULL
immune	NULL
responses	NULL
in	NULL
vitro	NULL
to	NULL
HIV	NULL
gp120	NULL
epitopes	NULL
,	NULL
TT	NULL
,	NULL
or	NULL
superan-tigen	NULL
,	NULL
and	NULL
that	NULL
macrophages	NULL
or	NULL
monocytes	NULL
can	NULL
present	NULL
Ag	NULL
effectively	NULL
only	NULL
to	NULL
T	NULL
cells	NULL
from	NULL
sensitized	NULL
donors	NULL
(	NULL
17-19	NULL
,	NULL
23	NULL
,	NULL
26	NULL
,	NULL
37	NULL
)	NULL
.	NULL

As	NULL
was	NULL
found	NULL
using	NULL
HIV	NULL
gp120	NULL
peptides	NULL
,	NULL
the	NULL
generation	NULL
of	NULL
responses	NULL
to	NULL
VZV	NULL
IE62	NULL
peptides	NULL
showed	NULL
that	NULL
DC	NULL
with	NULL
the	NULL
capacity	NULL
to	NULL
present	NULL
viral	NULL
peptides	NULL
to	NULL
naive	NULL
human	NULL
T	NULL
cells	NULL
are	NULL
present	NULL
among	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
564	NULL
NAIVE	NULL
T	NULL
CELL	NULL
RESPONSES	NULL
IN	NULL
VITRO	NULL
IDENTIFY	NULL
IMMUNOGENIC	NULL
PEPTIDES	NULL
FIGURE	NULL
3	NULL
.	NULL

|	NULL
In	NULL
vitro	NULL
CD4*	NULL
T	NULL
cell	NULL
proliferation	NULL
responses	NULL
to	NULL
VZV	NULL
IEG2	NULL
peptides	NULL
before	NULL
and	NULL
after	NULL
varicella	NULL
vaccination	NULL
.	NULL

T	NULL
cell-proliferative	NULL
responses	NULL
to	NULL
the	NULL
IE62	NULL
peptides	NULL
,	NULL
PI-P8	NULL
,	NULL
are	NULL
shown	NULL
for	NULL
do-mors	NULL
1	NULL
and	NULL
3	NULL
;	NULL
panels	NULL
IA	NULL
and	NULL
3A	NULL
show	NULL
responses	NULL
before	NULL
immunization	NULL
with	NULL
varicella	NULL
vaccine	NULL
.	NULL

Panels	NULL
1B	NULL
and	NULL
1C	NULL
,	NULL
and	NULL
3B	NULL
and	NULL
3C	NULL
,	NULL
show	NULL
postvaccination	NULL
responses	NULL
.	NULL

Panels	NULL
IA	NULL
and	NULL
3A	NULL
show	NULL
the	NULL
cpm	NULL
X10	NULL
3	NULL
cpm	NULL
X10	NULL
3	NULL
P2	NULL
P3	NULL
P4	NULL
P5	NULL
PS	NULL
P7	NULL
P8	NULL
mean	NULL
[	NULL
3HJthymidine	NULL
uptake	NULL
(	NULL
cpm	NULL
*	NULL
SE	NULL
)	NULL
from	NULL
replicate	NULL
wells	NULL
after	NULL
the	NULL
incubation	NULL
of	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
with	NULL
autologous	NULL
DC	NULL
alone	NULL
or	NULL
with	NULL
IEG2	NULL
peptides	NULL
.	NULL

Panels	NULL
IB	NULL
and	NULL
3B	NULL
show	NULL
mean	NULL
proliferative	NULL
responses	NULL
from	NULL
replicate	NULL
®	NULL
wells	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
donors	NULL
1	NULL
and	NULL
3	NULL
after	NULL
immunization	NULL
using	NULL
DC	NULL
as	NULL
APC	NULL
.	NULL

Panels	NULL
1C	NULL
and	NULL
3C	NULL
show	NULL
mean	NULL
proliferation	NULL
in	NULL
replicate	NULL
wells	NULL
when	NULL
CD4*	NULL
T	NULL
cells	NULL
obtained	NULL
after	NULL
immunization	NULL
were	NULL
incubated	NULL
with	NULL
autologous	NULL
monocytes	NULL
alone	NULL
or	NULL
IE62	NULL
peptides	NULL
and	NULL
monocytes	NULL
.	NULL

Data	NULL
with	NULL
peptides	NULL
indicate	NULL
the	NULL
maximum	NULL
response	NULL
observed	NULL
when	NULL
CD4*	NULL
T	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
pep	NULL
cpm	NULL
X10	NULL
DC+TC	NULL
P1	NULL
P2	NULL
P3	NULL
P4	NULL
P5	NULL
P6	NULL
P7	NULL
P8	NULL
DC+TCP1	NULL
P2	NULL
P3	NULL
P4	NULL
P5	NULL
P6	NULL
P7	NULL
P8	NULL
20	NULL
3B	NULL
15	NULL
*	NULL
*	NULL
*	NULL
o	NULL
o	NULL
*	NULL
40	NULL
E	NULL
a	NULL
o	NULL
5	NULL
0	NULL
DC+TCP1	NULL
P2	NULL
P3	NULL
P4	NULL
PS	NULL
P6	NULL
P7	NULL
P8	NULL
tide	NULL
concentrations	NULL
of	NULL
40	NULL
,	NULL
60	NULL
,	NULL
or	NULL
80	NULL
10.0	NULL
ug/tal	NULL
using	NULL
DC	NULL
as	NULL
APC	NULL
,	NULL
or	NULL
60	NULL
or	NULL
80	NULL
ug/tol	NULL
using	NULL
monocytes	NULL
as	NULL
APC	NULL
.	NULL

Results	NULL
are	NULL
indicated	NULL
only	NULL
if	NULL
at	NULL
least	NULL
2	NULL
concentrations	NULL
of	NULL
peptide	NULL
were	NULL
tested	NULL
.	NULL

The	NULL
asterisks	NULL
indicate	NULL
a	NULL
positive	NULL
response	NULL
in	NULL
peptide-stimulated	NULL
wells	NULL
compared	NULL
with	NULL
control	NULL
wells	NULL
,	NULL
defined	NULL
as	NULL
p	NULL
<	NULL
0.05	NULL
by	NULL
Student	NULL
's	NULL
£	NULL
test	NULL
for	NULL
two	NULL
means	NULL
.	NULL

1C	NULL
|	NULL
cpm	NULL
X10	NULL
M+TC	NULL
pi-	NULL
p2	NULL
p3	NULL
circulating	NULL
PBMC	NULL
populations	NULL
(	NULL
18	NULL
,	NULL
38	NULL
)	NULL
.	NULL

When	NULL
presented	NULL
by	NULL
DC	NULL
,	NULL
T	NULL
cells	NULL
from	NULL
each	NULL
of	NULL
seven	NULL
donors	NULL
responded	NULL
to	NULL
at	NULL
least	NULL
three	NULL
of	NULL
the	NULL
eight	NULL
IE62	NULL
peptides	NULL
and	NULL
70-100	NULL
%	NULL
of	NULL
the	NULL
donors	NULL
responded	NULL
to	NULL
P1	NULL
,	NULL
P4	NULL
,	NULL
and	NULL
P7	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
algorithms	NULL
for	NULL
probable	NULL
T	NULL
cell	NULL
epitopes	NULL
are	NULL
useful	NULL
to	NULL
predict	NULL
amino	NULL
acid	NULL
sequences	NULL
that	NULL
can	NULL
be	NULL
recognized	NULL
by	NULL
naive	NULL
T	NULL
cells	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
.	NULL

When	NULL
presented	NULL
by	NULL
monocytes	NULL
,	NULL
P1	NULL
and	NULL
P4	NULL
were	NULL
also	NULL
recognized	NULL
by	NULL
T	NULL
cells	NULL
from	NULL
80	NULL
and	NULL
100	NULL
%	NULL
of	NULL
donors	NULL
after	NULL
vaccination	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
peptides	NULL
selected	NULL
with	NULL
MHC	NULL
class	NULL
I	NULL
algorithms	NULL
were	NULL
immunogenic	NULL
in	NULL
CD4	NULL
*	NULL
T	NULL
cell/MHC	NULL
class	NULL
II	NULL
interactions	NULL
has	NULL
also	NULL
been	NULL
noted	NULL
with	NULL
other	NULL
microbial	NULL
proteins	NULL
and	NULL
probably	NULL
reflects	NULL
the	NULL
relative	NULL
promiscuity	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
peptide	NULL
binding	NULL
(	NULL
39	NULL
,	NULL
40	NULL
)	NULL
.	NULL

The	NULL
isolation	NULL
of	NULL
DC	NULL
from	NULL
PBMC	NULL
initially	NULL
yields	NULL
immature	NULL
DC	NULL
(	NULL
37	NULL
)	NULL
.	NULL

The	NULL
DC	NULL
enrichment	NULL
protocol	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
included	NULL
a	NULL
2-day	NULL
incubation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
autologous	NULL
lymphocytes	NULL
to	NULL
allow	NULL
maturation	NULL
of	NULL
DC	NULL
to	NULL
a	NULL
strong	NULL
Ag-presentation	NULL
phenotype	NULL
(	NULL
25	NULL
)	NULL
.	NULL

By	NULL
the	NULL
second	NULL
day	NULL
in	NULL
culture	NULL
,	NULL
DC	NULL
had	NULL
the	NULL
morphological	NULL
characteristics	NULL
of	NULL
mature	NULL
cells	NULL
,	NULL
including	NULL
long	NULL
cy-toplasmic	NULL
processses	NULL
,	NULL
irregularly	NULL
shaped	NULL
nuclei	NULL
,	NULL
and	NULL
few	NULL
cytoplas-	NULL
p4	NULL
pS	NULL
p6	NULL
p7	NULL
p8	NULL
cpm	NULL
x10	NULL
M+TC	NULL
pi	NULL
p2	NULL
p3	NULL
p4	NULL
p§	NULL
p6	NULL
p7	NULL
p8	NULL
mic	NULL
organelles	NULL
.	NULL

Furthermore	NULL
,	NULL
DC	NULL
were	NULL
observed	NULL
in	NULL
conjunction	NULL
with	NULL
clusters	NULL
of	NULL
lymphocytes	NULL
and	NULL
exhibited	NULL
the	NULL
functional	NULL
capacity	NULL
to	NULL
elicit	NULL
proliferation	NULL
of	NULL
naive	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
IE62	NULL
peptides	NULL
at	NULL
this	NULL
time	NULL
point	NULL
.	NULL

Ag	NULL
presentation	NULL
by	NULL
DC	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
involve	NULL
binding	NULL
of	NULL
CD40	NULL
to	NULL
CD40	NULL
ligand	NULL
on	NULL
T	NULL
cells	NULL
(	NULL
41	NULL
,	NULL
42	NULL
)	NULL
.	NULL

This	NULL
interaction	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
marked	NULL
increase	NULL
in	NULL
IL-12	NULL
production	NULL
and	NULL
favors	NULL
a	NULL
predominantly	NULL
Th1	NULL
response	NULL
,	NULL
which	NULL
is	NULL
the	NULL
cytokine	NULL
pattern	NULL
that	NULL
we	NULL
have	NULL
observed	NULL
during	NULL
the	NULL
acquisition	NULL
of	NULL
primary	NULL
immunity	NULL
to	NULL
VZV	NULL
(	NULL
43	NULL
)	NULL
.	NULL

According	NULL
to	NULL
current	NULL
models	NULL
of	NULL
DC	NULL
development	NULL
,	NULL
uncultured	NULL
DC	NULL
correspond	NULL
to	NULL
less	NULL
mature	NULL
cells	NULL
in	NULL
vivo	NULL
;	NULL
these	NULL
cells	NULL
express	NULL
low	NULL
levels	NULL
of	NULL
MHC	NULL
and	NULL
costimulatory	NULL
molecules	NULL
and	NULL
high	NULL
levels	NULL
of	NULL
FcR	NULL
and	NULL
mannose	NULL
receptors	NULL
and	NULL
function	NULL
primarily	NULL
to	NULL
take	NULL
up	NULL
and	NULL
process	NULL
Ag	NULL
(	NULL
10	NULL
,	NULL
37	NULL
)	NULL
.	NULL

Uncultured	NULL
,	NULL
immature	NULL
DC	NULL
process	NULL
foreign	NULL
proteins	NULL
and	NULL
present	NULL
peptides	NULL
to	NULL
memory	NULL
T	NULL
cells	NULL
efficiently	NULL
but	NULL
do	NULL
not	NULL
sensitize	NULL
naive	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
subset	NULL
of	NULL
DC	NULL
that	NULL
process	NULL
and	NULL
present	NULL
Ag	NULL
to	NULL
naive	NULL
T	NULL
cells	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
derived	NULL
from	NULL
CD2	NULL
precursors	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
fact	NULL
that	NULL
we	NULL
detected	NULL
memory	NULL
responses	NULL
to	NULL
whole	NULL
Ag	NULL
,	NULL
such	NULL
as	NULL
TT	NULL
,	NULL
as	NULL
well	NULL
as	NULL
proliferation	NULL
of	NULL
naive	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
565	NULL
Table	NULL
III	NULL
.	NULL

-	NULL
Summary	NULL
of	NULL
proliferative	NULL
responses	NULL
to	NULL
VZV	NULL
IE6G2	NULL
peptides	NULL
by	NULL
CD4+	NULL
T	NULL
cells	NULL
obtained	NULL
from	NULL
donors	NULL
before	NULL
and	NULL
after	NULL
varicella	NULL
immunization	NULL
Immunogenic	NULL
No	NULL
.	NULL

Donor	NULL
APC	NULL
P1	NULL
P2	NULL
P3	NULL
P4	NULL
P5	NULL
P6	NULL
P7	NULL
P8	NULL
Peptides	NULL
1	NULL
Naive	NULL
DC	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
8/8	NULL
``	NULL
Immunized	NULL
Mono	NULL
[	NULL
+	NULL
]	NULL
[	NULL
+	NULL
]	NULL
[	NULL
+	NULL
]	NULL
[	NULL
+	NULL
]	NULL
[	NULL
+	NULL
]	NULL
[	NULL
+	NULL
]	NULL
[	NULL
+	NULL
]	NULL
-	NULL
7/8	NULL
2	NULL
Naive	NULL
DC	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
3/6	NULL
Immunized	NULL
Mono	NULL
[	NULL
+	NULL
]	NULL
+	NULL
[	NULL
+	NULL
]	NULL
+	NULL
+	NULL
[	NULL
+	NULL
]	NULL
[	NULL
<	NULL
]	NULL
677	NULL
3	NULL
Naive	NULL
DC	NULL
-	NULL
-	NULL
+	NULL
+	NULL
-	NULL
+	NULL
+	NULL
-	NULL
4/8	NULL
Immunized	NULL
Mono	NULL
[	NULL
-	NULL
]	NULL
+	NULL
[	NULL
+	NULL
]	NULL
[	NULL
+	NULL
]	NULL
+	NULL
[	NULL
+	NULL
]	NULL
[	NULL
+	NULL
]	NULL
+	NULL
7/8	NULL
4a	NULL
Naive	NULL
DC	NULL
-	NULL
+	NULL
+	NULL
+	NULL
+	NULL
-	NULL
-	NULL
+	NULL
5/8	NULL
Immunized	NULL
Mono	NULL
+	NULL
-	NULL
-	NULL
[	NULL
+	NULL
]	NULL
[	NULL
+	NULL
]	NULL
+	NULL
[	NULL
<	NULL
]	NULL
[	NULL
+	NULL
]	NULL
5/8	NULL
5	NULL
Naive	NULL
DC	NULL
+	NULL
-	NULL
-	NULL
+	NULL
+	NULL
-	NULL
3/6	NULL
Immunized	NULL
Mono	NULL
[	NULL
+	NULL
]	NULL
[	NULL
-	NULL
]	NULL
[	NULL
-	NULL
]	NULL
+	NULL
[	NULL
+	NULL
]	NULL
+	NULL
-	NULL
[	NULL
<	NULL
]	NULL
4/8	NULL
``	NULL
Ratios	NULL
indicate	NULL
positive	NULL
peptide	NULL
responses	NULL
per	NULL
total	NULL
number	NULL
of	NULL
peptides	NULL
tested	NULL
in	NULL
each	NULL
donor	NULL
;	NULL
a	NULL
blank	NULL
indicates	NULL
that	NULL
the	NULL
peptide	NULL
was	NULL
not	NULL
tested	NULL
with	NULL
at	NULL
least	NULL
two	NULL
peptide	NULL
concentrations	NULL
.	NULL

*	NULL
Brackets	NULL
indicate	NULL
responses	NULL
that	NULL
were	NULL
concordant	NULL
with	NULL
those	NULL
of	NULL
naive	NULL
T	NULL
cells	NULL
from	NULL
the	NULL
same	NULL
donor	NULL
when	NULL
monocytes	NULL
were	NULL
used	NULL
as	NULL
APC	NULL
for	NULL
IE62	NULL
peptides	NULL
postvaccination	NULL
.	NULL

100	NULL
;	NULL
-|	NULL
=	NULL
O	NULL
Vaccine=DC	NULL
90	NULL
:	NULL
Vaccine=monocyte	NULL
_	NULL
NI	NULL
?	NULL

80	NULL
70	NULL
FIGURE	NULL
4	NULL
.	NULL

Comparison	NULL
of	NULL
T	NULL
cell	NULL
prolifer-	NULL
ation	NULL
responses	NULL
to	NULL
VZV	NULL
IE6G2	NULL
peptides	NULL
in	NULL
nat	NULL
urally	NULL
immune	NULL
donors	NULL
,	NULL
naive	NULL
donors	NULL
,	NULL
and	NULL
do-	NULL
60	NULL
nors	NULL
immunized	NULL
with	NULL
varicella	NULL
vaccine	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
naturally	NULL
immune	NULL
(	NULL
Nl	NULL
)	NULL
subjects	NULL
(	NULL
black	NULL
bars	NULL
)	NULL
who	NULL
had	NULL
detectable	NULL
T	NULL
cell	NULL
proliferation	NULL
to	NULL
IE62	NULL
peptides	NULL
is	NULL
compared	NULL
with	NULL
those	NULL
of	NULL
naive	NULL
donors	NULL
(	NULL
gray	NULL
bars	NULL
)	NULL
;	NULL
the	NULL
percentage	NULL
of	NULL
donors	NULL
immunized	NULL
with	NULL
varicella	NULL
vaccine	NULL
who	NULL
had	NULL
responses	NULL
postvaccination	NULL
in	NULL
cultures	NULL
with	NULL
DC	NULL
as	NULL
APC	NULL
is	NULL
shown	NULL
with	NULL
open	NULL
bars	NULL
;	NULL
the	NULL
percentage	NULL
with	NULL
responses	NULL
using	NULL
monocytes	NULL
as	NULL
APC	NULL
is	NULL
shown	NULL
with	NULL
hatched	NULL
bars	NULL
.	NULL

The	NULL
horizontal	NULL
axis	NULL
indicates	NULL
the	NULL
peptide	NULL
tested	NULL
,	NULL
P1-P8	NULL
.	NULL

50	NULL
%	NULL
o	NULL
40	NULL
30	NULL
20	NULL
10	NULL
&	NULL
Q	NULL
§	NULL
§	NULL
C	NULL
§	NULL
C	NULL
§	NULL
§	NULL
§	NULL
Y	NULL
¢	NULL
§	NULL
&	NULL
&	NULL
o	NULL
R	NULL
|	NULL
g	NULL
C	NULL
'	NULL
|	NULL
§	NULL
'	NULL
§	NULL
.	NULL

§	NULL
&	NULL
§	NULL
§	NULL
§	NULL
C	NULL
§	NULL
C	NULL
§	NULL
C	NULL
§	NULL
§	NULL
¢	NULL
5	NULL
-	NULL
RS	NULL
R	NULL
'	NULL
|	NULL
Y	NULL
|	NULL
g	NULL
|	NULL
§	NULL
R	NULL
§	NULL
§	NULL
§	NULL
§	NULL
.	NULL

§	NULL
_	NULL
§	NULL
¢	NULL
-|	NULL
§	NULL
|	NULL
g	NULL
§	NULL
$	NULL
§	NULL
§	NULL
§	NULL
§	NULL
C	NULL
§	NULL
C	NULL
&	NULL
iY	NULL
AOTC	NULL
Es	NULL
§	NULL
&	NULL
S	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
S	NULL
S	NULL
§	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
&	NULL
t	NULL
7	NULL
oromo	NULL
oooh	NULL
g	NULL
P1	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
566	NULL
NAIVE	NULL
T	NULL
CELL	NULL
RESPONSES	NULL
IN	NULL
VITRO	NULL
IDENTIFY	NULL
IMMUNOGENIC	NULL
PEPTIDES	NULL
T	NULL
cells	NULL
to	NULL
IE62	NULL
peptides	NULL
,	NULL
suggests	NULL
that	NULL
both	NULL
immature	NULL
and	NULL
mature	NULL
forms	NULL
of	NULL
DC	NULL
were	NULL
present	NULL
under	NULL
the	NULL
culture	NULL
conditions	NULL
that	NULL
we	NULL
used	NULL
.	NULL

Immature	NULL
as	NULL
well	NULL
as	NULL
mature	NULL
DC	NULL
are	NULL
also	NULL
detected	NULL
when	NULL
human	NULL
DC	NULL
are	NULL
derived	NULL
in	NULL
vitro	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
granulocyte-mac-rophage	NULL
CSF	NULL
and	NULL
TNF-a	NULL
,	NULL
as	NULL
defined	NULL
by	NULL
their	NULL
Ag-processing	NULL
and	NULL
-presentation	NULL
capacities	NULL
(	NULL
26	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
confirming	NULL
that	NULL
cultured	NULL
DC	NULL
are	NULL
required	NULL
for	NULL
priming	NULL
naive	NULL
T	NULL
cell	NULL
responses	NULL
to	NULL
viral	NULL
peptides	NULL
in	NULL
vitro	NULL
,	NULL
our	NULL
experiments	NULL
extended	NULL
previous	NULL
observations	NULL
with	NULL
VZV	NULL
Ag	NULL
by	NULL
analyzing	NULL
the	NULL
relationship	NULL
between	NULL
naive	NULL
responses	NULL
generated	NULL
in	NULL
vitro	NULL
with	NULL
those	NULL
elicited	NULL
in	NULL
the	NULL
same	NULL
donors	NULL
after	NULL
in	NULL
vivo	NULL
sensitization	NULL
to	NULL
IE62	NULL
peptides	NULL
.	NULL

The	NULL
specific	NULL
patterns	NULL
of	NULL
IE62	NULL
peptide	NULL
recognition	NULL
observed	NULL
when	NULL
the	NULL
primary	NULL
response	NULL
of	NULL
VZV-susceptible	NULL
donors	NULL
was	NULL
evaluated	NULL
in	NULL
vitro	NULL
correlated	NULL
with	NULL
responses	NULL
documented	NULL
after	NULL
VZV	NULL
immunity	NULL
was	NULL
induced	NULL
in	NULL
vivo	NULL
by	NULL
immunization	NULL
with	NULL
live-attenuated	NULL
varicella	NULL
vaccine	NULL
.	NULL

A	NULL
match	NULL
between	NULL
pre-	NULL
and	NULL
postvaccination	NULL
responses	NULL
to	NULL
IE6G2	NULL
peptides	NULL
occurred	NULL
in	NULL
69	NULL
%	NULL
of	NULL
comparisons	NULL
using	NULL
monocytes	NULL
as	NULL
APC	NULL
;	NULL
the	NULL
positive-predictive	NULL
value	NULL
was	NULL
82	NULL
%	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
assessment	NULL
of	NULL
naive	NULL
T	NULL
cell	NULL
responses	NULL
in	NULL
vitro	NULL
has	NULL
potential	NULL
value	NULL
for	NULL
predicting	NULL
the	NULL
immunogencity	NULL
of	NULL
viral	NULL
peptides	NULL
in	NULL
vivo	NULL
.	NULL

Because	NULL
failure	NULL
to	NULL
demonstrate	NULL
a	NULL
naive	NULL
T	NULL
cell	NULL
response	NULL
to	NULL
a	NULL
peptide	NULL
had	NULL
less	NULL
predictive	NULL
value	NULL
than	NULL
a	NULL
positive	NULL
response	NULL
,	NULL
some	NULL
peptides	NULL
that	NULL
are	NULL
immunogenic	NULL
in	NULL
vivo	NULL
would	NULL
be	NULL
excluded	NULL
by	NULL
this	NULL
criterion	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
case	NULL
of	NULL
large	NULL
viral	NULL
proteins	NULL
like	NULL
IE62	NULL
that	NULL
have	NULL
many	NULL
potential	NULL
T	NULL
cell	NULL
epitopes	NULL
,	NULL
the	NULL
observation	NULL
that	NULL
a	NULL
positive	NULL
response	NULL
to	NULL
a	NULL
particular	NULL
peptide	NULL
in	NULL
vitro	NULL
suggests	NULL
that	NULL
it	NULL
will	NULL
also	NULL
be	NULL
immunogenic	NULL
in	NULL
vivo	NULL
and	NULL
should	NULL
help	NULL
to	NULL
limit	NULL
the	NULL
options	NULL
to	NULL
be	NULL
considered	NULL
in	NULL
subunit	NULL
vaccine	NULL
design	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
a	NULL
complete	NULL
match	NULL
between	NULL
responses	NULL
before	NULL
and	NULL
after	NULL
vaccination	NULL
is	NULL
consistent	NULL
with	NULL
an	NULL
evaluation	NULL
of	NULL
HIV	NULL
immunity	NULL
after	NULL
initial	NULL
infection	NULL
that	NULL
showed	NULL
a	NULL
progressive	NULL
increase	NULL
in	NULL
the	NULL
number	NULL
of	NULL
HIV	NULL
epitopes	NULL
recognized	NULL
by	NULL
T	NULL
cells	NULL
over	NULL
time	NULL
,	NULL
as	NULL
well	NULL
as	NULL
a	NULL
loss	NULL
of	NULL
reactivity	NULL
to	NULL
some	NULL
epitopes	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Similarities	NULL
in	NULL
IE62	NULL
peptide	NULL
recognition	NULL
were	NULL
also	NULL
observed	NULL
when	NULL
the	NULL
responses	NULL
of	NULL
VZV-susceptible	NULL
donors	NULL
were	NULL
compared	NULL
with	NULL
those	NULL
of	NULL
donors	NULL
who	NULL
had	NULL
naturally	NULL
acquired	NULL
immunity	NULL
to	NULL
VZV	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
IE62	NULL
peptides	NULL
,	NULL
P1	NULL
and	NULL
P4	NULL
,	NULL
that	NULL
stimulated	NULL
naive	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
effectively	NULL
in	NULL
vitro	NULL
,	NULL
were	NULL
also	NULL
recognized	NULL
by	NULL
T	NULL
cells	NULL
from	NULL
most	NULL
donors	NULL
with	NULL
natural	NULL
immunity	NULL
;	NULL
conversely	NULL
,	NULL
recognition	NULL
of	NULL
P2	NULL
and	NULL
P8	NULL
was	NULL
limited	NULL
in	NULL
both	NULL
groups	NULL
.	NULL

A	NULL
somewhat	NULL
broader	NULL
recognition	NULL
of	NULL
IEG62	NULL
peptides	NULL
was	NULL
noted	NULL
in	NULL
naturally	NULL
immune	NULL
individuals	NULL
compared	NULL
with	NULL
vaccine	NULL
recipients	NULL
,	NULL
which	NULL
could	NULL
reflect	NULL
an	NULL
expanding	NULL
T	NULL
cell	NULL
repertoire	NULL
induced	NULL
by	NULL
re-exposures	NULL
to	NULL
varicella	NULL
or	NULL
by	NULL
subclinical	NULL
reactivations	NULL
of	NULL
the	NULL
endogenous	NULL
latent	NULL
virus	NULL
in	NULL
these	NULL
donors	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

The	NULL
donors	NULL
in	NULL
these	NULL
experiments	NULL
were	NULL
selected	NULL
for	NULL
their	NULL
susceptiblity	NULL
to	NULL
VZV	NULL
and	NULL
represented	NULL
an	NULL
``	NULL
outbred	NULL
``	NULL
population	NULL
expected	NULL
to	NULL
have	NULL
diverse	NULL
MHC	NULL
class	NULL
II	NULL
alleles	NULL
.	NULL

Nevertheless	NULL
,	NULL
relatively	NULL
broad	NULL
recognition	NULL
of	NULL
VZV	NULL
peptides	NULL
by	NULL
naive	NULL
T	NULL
cells	NULL
and	NULL
by	NULL
T	NULL
cells	NULL
obtained	NULL
after	NULL
in	NULL
vivo	NULL
sensitization	NULL
of	NULL
the	NULL
donors	NULL
was	NULL
demon-strated	NULL
.	NULL

Naive	NULL
donors	NULL
had	NULL
T	NULL
cells	NULL
that	NULL
proliferated	NULL
in	NULL
response	NULL
to	NULL
a	NULL
mean	NULL
of	NULL
65	NULL
%	NULL
of	NULL
the	NULL
IE62	NULL
peptides	NULL
and	NULL
T	NULL
cells	NULL
from	NULL
immunized	NULL
donors	NULL
responded	NULL
to	NULL
a	NULL
mean	NULL
of	NULL
88	NULL
%	NULL
of	NULL
the	NULL
peptides	NULL
using	NULL
monocytes	NULL
as	NULL
APC	NULL
.	NULL

When	NULL
memory	NULL
responses	NULL
to	NULL
the	NULL
VZV	NULL
IEG2	NULL
peptides	NULL
were	NULL
evaluated	NULL
in	NULL
naturally	NULL
immune	NULL
individuals	NULL
who	NULL
had	NULL
widely	NULL
varying	NULL
MHC	NULL
haplotypes	NULL
,	NULL
all	NULL
donors	NULL
showed	NULL
broad	NULL
recognition	NULL
of	NULL
VZV	NULL
peptides	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
sensitization	NULL
of	NULL
T	NULL
cells	NULL
from	NULL
all	NULL
,	NULL
or	NULL
almost	NULL
all	NULL
,	NULL
donors	NULL
to	NULL
a	NULL
single	NULL
peptide	NULL
such	NULL
as	NULL
P4	NULL
,	NULL
suggests	NULL
that	NULL
these	NULL
more	NULL
immunogenic	NULL
peptides	NULL
represent	NULL
epitopes	NULL
that	NULL
can	NULL
mediate	NULL
MHC	NULL
class	NULL
II/TCR	NULL
interactions	NULL
despite	NULL
genetic	NULL
variations	NULL
.	NULL

The	NULL
value	NULL
of	NULL
using	NULL
primary	NULL
in	NULL
vitro	NULL
sensitization	NULL
to	NULL
identify	NULL
peptides	NULL
that	NULL
are	NULL
immunogenic	NULL
across	NULL
diverse	NULL
class	NULL
II	NULL
MHC	NULL
types	NULL
will	NULL
require	NULL
confirmation	NULL
in	NULL
larger	NULL
populations	NULL
when	NULL
DC	NULL
separations	NULL
can	NULL
be	NULL
done	NULL
more	NULL
efficiently	NULL
and	NULL
with	NULL
smaller	NULL
volumes	NULL
of	NULL
blood	NULL
.	NULL

However	NULL
,	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
conserved	NULL
influenza	NULL
A	NULL
hemagglutinin	NULL
epitopes	NULL
,	NULL
defined	NULL
using	NULL
synthetic	NULL
peptides	NULL
,	NULL
has	NULL
been	NULL
described	NULL
after	NULL
immunization	NULL
of	NULL
donors	NULL
with	NULL
diverse	NULL
MHC	NULL
haplotypes	NULL
using	NULL
a	NULL
subunit	NULL
influenza	NULL
vaccine	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Other	NULL
studies	NULL
of	NULL
in	NULL
vitro	NULL
sensitization	NULL
using	NULL
HIV	NULL
peptides	NULL
or	NULL
the	NULL
hapten	NULL
,	NULL
TNP	NULL
,	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
same	NULL
peptides	NULL
induced	NULL
proliferation	NULL
of	NULL
naive	NULL
T	NULL
cell	NULL
proliferation	NULL
responses	NULL
despite	NULL
differences	NULL
in	NULL
MHC	NULL
alleles	NULL
(	NULL
12	NULL
,	NULL
47	NULL
)	NULL
.	NULL

An	NULL
analysis	NULL
of	NULL
memory	NULL
responses	NULL
to	NULL
measles	NULL
peptides	NULL
in	NULL
vaccinated	NULL
and	NULL
naturally	NULL
immune	NULL
donors	NULL
also	NULL
identified	NULL
several	NULL
peptides	NULL
that	NULL
were	NULL
commonly	NULL
recognized	NULL
by	NULL
T	NULL
cells	NULL
from	NULL
an	NULL
HLA-diverse	NULL
donor	NULL
population	NULL
(	NULL
48	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
its	NULL
value	NULL
for	NULL
understanding	NULL
the	NULL
cellular	NULL
interactions	NULL
and	NULL
epitope	NULL
characteristics	NULL
that	NULL
are	NULL
required	NULL
to	NULL
generate	NULL
adaptive	NULL
immunity	NULL
,	NULL
the	NULL
analysis	NULL
of	NULL
primary	NULL
CD4	NULL
and	NULL
CD8	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
viral	NULL
peptides	NULL
in	NULL
vitro	NULL
using	NULL
DC-based	NULL
assays	NULL
may	NULL
be	NULL
useful	NULL
for	NULL
designing	NULL
subunit	NULL
vaccines	NULL
against	NULL
human	NULL
pathogens	NULL
,	NULL
especially	NULL
those	NULL
for	NULL
which	NULL
no	NULL
animal	NULL
model	NULL
is	NULL
available	NULL
(	NULL
49	NULL
,	NULL
50	NULL
)	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Julia	NULL
Martinsen	NULL
for	NULL
assistance	NULL
.	NULL

The	NULL
live	NULL
attenuated	NULL
varicella	NULL
vaccine	NULL
was	NULL
provided	NULL
by	NULL
Merck	NULL
.	NULL

Informed	NULL
consent	NULL
was	NULL
obtained	NULL
from	NULL
participants	NULL
according	NULL
to	NULL
the	NULL
U.S.	NULL
Department	NULL
of	NULL
Health	NULL
and	NULL
Human	NULL
Services	NULL
and	NULL
Stanford	NULL
University	NULL
guidelines	NULL
for	NULL
research	NULL
involving	NULL
human	NULL
subjects	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Arvin	NULL
,	NULL
A.	NULL
M.	NULL
1995	NULL
.	NULL

Varicella-Zoster	NULL
virus	NULL
.	NULL

In	NULL
Virology	NULL
.	NULL

B	NULL
.	NULL

Fields	NULL
,	NULL
ed	NULL
.	NULL

Raven	NULL
Press	NULL
,	NULL
New	NULL
York	NULL
,	NULL
pp	NULL
.	NULL

2547-2586	NULL
.	NULL

2	NULL
.	NULL

Lungu	NULL
,	NULL
O.	NULL
,	NULL
P.	NULL
W.	NULL
Annunziato	NULL
,	NULL
A.	NULL
Gershon	NULL
,	NULL
S.	NULL
M.	NULL
Staugaitis	NULL
,	NULL
D.	NULL
Josefson	NULL
,	NULL
P.	NULL
LaRussa	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Silverstein	NULL
.	NULL

1995	NULL
.	NULL

Reactivated	NULL
and	NULL
latent	NULL
varicella-zoster	NULL
virus	NULL
in	NULL
human	NULL
dorsal	NULL
root	NULL
ganglia	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:10980	NULL
.	NULL

3	NULL
.	NULL

Arvin	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
J.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
R.	NULL
Redman	NULL
.	NULL

1996	NULL
.	NULL

Varicella-zoster	NULL
virus	NULL
:	NULL
aspects	NULL
of	NULL
pathogenesis	NULL
and	NULL
host	NULL
response	NULL
to	NULL
natural	NULL
infection	NULL
and	NULL
varicella	NULL
vaccine	NULL
.	NULL

In	NULL
Advances	NULL
in	NULL
Virus	NULL
Research	NULL
,	NULL
Vol	NULL
.	NULL

46	NULL
.	NULL

F.	NULL
A.	NULL
Murphy	NULL
,	NULL
A.	NULL
J.	NULL
Shatkin	NULL
,	NULL
and	NULL
K.	NULL
Maramorosh	NULL
,	NULL
eds	NULL
.	NULL

Academic	NULL
Press	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
pp	NULL
.	NULL

265-309	NULL
.	NULL

4	NULL
.	NULL

Hayward	NULL
,	NULL
A.	NULL
,	NULL
O.	NULL
Pontesilli	NULL
,	NULL
M.	NULL
Herberger	NULL
,	NULL
M.	NULL
Laszlo	NULL
,	NULL
and	NULL
M.	NULL
Levin	NULL
.	NULL

1986	NULL
.	NULL

Specific	NULL
lysis	NULL
of	NULL
varicella-zoster	NULL
virus-infected	NULL
B	NULL
lymphoblasts	NULL
by	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

58:179	NULL
.	NULL

5	NULL
.	NULL

Hayward	NULL
,	NULL
A.	NULL
R.	NULL
1990	NULL
.	NULL

T-cell	NULL
responses	NULL
to	NULL
predicted	NULL
amphipathic	NULL
peptides	NULL
of	NULL
varicella-zoster	NULL
virus	NULL
glycoproteins	NULL
II	NULL
and	NULL
IV	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:651	NULL
.	NULL

6	NULL
.	NULL

Hickling	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
L.	NULL
K.	NULL
Borysiewicz	NULL
,	NULL
and	NULL
J.	NULL
G.	NULL
P.	NULL
Sissons	NULL
.	NULL

1987	NULL
.	NULL

Varicella-zoster	NULL
virus	NULL
specific	NULL
cytotoxic	NULL
T	NULL
lympohcytes	NULL
(	NULL
TC	NULL
)	NULL
:	NULL
detection	NULL
and	NULL
frequency	NULL
analysis	NULL
of	NULL
HLA	NULL
class	NULL
T-restricted	NULL
Te	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:3463	NULL
.	NULL

7	NULL
.	NULL

Sharp	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
Terada	NULL
,	NULL
A.	NULL
Wilson	NULL
,	NULL
S.	NULL
Nader	NULL
,	NULL
P.	NULL
E.	NULL
Kinchington	NULL
,	NULL
W.	NULL
Ruyechan	NULL
,	NULL
J.	NULL
Hay	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Arvin	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
kinetics	NULL
and	NULL
protein	NULL
specificity	NULL
of	NULL
T-lymphocyte	NULL
cytotoxicity	NULL
in	NULL
healthy	NULL
adults	NULL
immunized	NULL
with	NULL
live	NULL
attenuated	NULL
varicella	NULL
vaccine	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

165:852	NULL
.	NULL

8	NULL
.	NULL

Arvin	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
M.	NULL
Sharp	NULL
,	NULL
S.	NULL
Smith	NULL
,	NULL
C.	NULL
M.	NULL
Koropchak	NULL
,	NULL
P.	NULL
S.	NULL
Diaz	NULL
,	NULL
P.	NULL
Kinchington	NULL
,	NULL
W.	NULL
Ruyechan	NULL
,	NULL
and	NULL
J.	NULL
Hay	NULL
.	NULL

1991	NULL
.	NULL

Equivalent	NULL
recognition	NULL
of	NULL
a	NULL
varicella-zoster	NULL
virus	NULL
immediate	NULL
early	NULL
protein	NULL
(	NULL
IB62	NULL
)	NULL
and	NULL
glycoprotein	NULL
I	NULL
by	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
of	NULL
cither	NULL
CD4*	NULL
or	NULL
CD8	NULL
*	NULL
phenotype	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

146:257	NULL
.	NULL

9	NULL
.	NULL

Zhang	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Cosyns	NULL
,	NULL
M.	NULL
J.	NULL
Levin	NULL
,	NULL
and	NULL
A.	NULL
R.	NULL
Hayward	NULL
.	NULL

1994	NULL
.	NULL

Cytokine	NULL
production	NULL
in	NULL
varicella	NULL
zoster	NULL
virus-stimulated	NULL
limiting	NULL
dilution	NULL
lymphocyte	NULL
cultures	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

98:128	NULL
.	NULL

10	NULL
.	NULL

Steinman	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
M.	NULL
Pack	NULL
,	NULL
and	NULL
K.	NULL
Inaba	NULL
.	NULL

1997	NULL
.	NULL

Dendritic	NULL
cell	NULL
development	NULL
and	NULL
maturation	NULL
.	NULL

Adv	NULL
.	NULL

Exp	NULL
.	NULL

Med	NULL
.	NULL

Biol	NULL
.	NULL

417:1	NULL
.	NULL

11	NULL
.	NULL

Austyn	NULL
,	NULL
J.	NULL
M.	NULL
1987	NULL
.	NULL

Lymphoid	NULL
dendritic	NULL
cells	NULL
.	NULL

Immunology	NULL
62:161	NULL
.	NULL

12	NULL
.	NULL

Macatonia	NULL
S.	NULL
E.	NULL
,	NULL
P.	NULL
M.	NULL
Taylor	NULL
,	NULL
S.	NULL
C.	NULL
Knight	NULL
,	NULL
and	NULL
B	NULL
.	NULL

A.	NULL
Askonas	NULL
.	NULL

1989	NULL
.	NULL

Primary	NULL
stimulation	NULL
by	NULL
dendritic	NULL
cells	NULL
induces	NULL
antiviral	NULL
proliferative	NULL
and	NULL
cytotoxic	NULL
T	NULL
cell	NULL
responses	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

169:1255	NULL
.	NULL

13	NULL
.	NULL

Hauser	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
S.	NULL
I.	NULL
Katz	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
and	NULL
expansion	NULL
of	NULL
hapten-	NULL
and	NULL
protein-specific	NULL
T	NULL
helper	NULL
cells	NULL
from	NULL
nonsensitized	NULL
mice	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
:	NULL
5625	NULL
.	NULL

14	NULL
.	NULL

Inaba	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1985	NULL
.	NULL

Protein-specific	NULL
helper	NULL
T-lymphocyte	NULL
formation	NULL
initiated	NULL
by	NULL
dendritic	NULL
cells	NULL
.	NULL

Science	NULL
229:475	NULL
.	NULL

15	NULL
.	NULL

Nonacs	NULL
,	NULL
R.	NULL
,	NULL
C.	NULL
Humborg	NULL
,	NULL
J.	NULL
P.	NULL
Tam	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1992	NULL
.	NULL

Mechanisms	NULL
of	NULL
mouse	NULL
spleen	NULL
dendritic	NULL
cell	NULL
function	NULL
in	NULL
the	NULL
generation	NULL
of	NULL
influenza-specific	NULL
,	NULL
cytolytic	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:519	NULL
.	NULL

16	NULL
.	NULL

Inaba	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
P.	NULL
Metlay	NULL
,	NULL
M.	NULL
T.	NULL
Crowley	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1990	NULL
.	NULL

Dendritic	NULL
cells	NULL
pulsed	NULL
with	NULL
protein	NULL
antigens	NULL
in	NULL
vitro	NULL
can	NULL
prime	NULL
antigen-specific	NULL
,	NULL
MHC-restricted	NULL
T	NULL
cells	NULL
in	NULL
situ	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
(	NULL
2	NULL
)	NULL
:631	NULL
.	NULL

17	NULL
.	NULL

Mehta-Damani	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Markowicz	NULL
,	NULL
and	NULL
E.	NULL
G.	NULL
Engleman	NULL
.	NULL

1994	NULL
.	NULL

Generation	NULL
of	NULL
antigen-specific	NULL
CD8	NULL
*	NULL
CTLS	NULL
from	NULL
naive	NULL
precursors	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:996	NULL
.	NULL

18	NULL
.	NULL

Mechta-Damani	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Markowicz	NULL
,	NULL
and	NULL
E.	NULL
G.	NULL
Engleman	NULL
.	NULL

1995	NULL
.	NULL

Generation	NULL
of	NULL
antigen-specific	NULL
DC4*	NULL
T	NULL
cell	NULL
lines	NULL
from	NULL
naive	NULL
precursors	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25	NULL
:	NULL
1206	NULL
.	NULL

19	NULL
.	NULL

Marland	NULL
,	NULL
G.	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Bakker	NULL
,	NULL
G.	NULL
J.	NULL
Adema	NULL
,	NULL
and	NULL
C.	NULL
G.	NULL
Figdor	NULL
.	NULL

1996	NULL
.	NULL

Dendritic	NULL
cells	NULL
in	NULL
immune	NULL
response	NULL
induction	NULL
.	NULL

Stem	NULL
Cells	NULL
14:501	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

Takamizawa	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Rivas	NULL
,	NULL
F.	NULL
Fagnoni	NULL
,	NULL
C.	NULL
Benike	NULL
,	NULL
J.	NULL
Kosek	NULL
,	NULL
H.	NULL
Hyakawa	NULL
,	NULL
and	NULL
E.	NULL
G.	NULL
Engleman	NULL
.	NULL

1997	NULL
.	NULL

Dendritic	NULL
cells	NULL
that	NULL
process	NULL
and	NULL
present	NULL
nominal	NULL
antigens	NULL
to	NULL
naive	NULL
T	NULL
lymphocytes	NULL
are	NULL
derived	NULL
from	NULL
CD2*	NULL
precursors	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158	NULL
:	NULL
2134	NULL
.	NULL

Bhardwaj	NULL
,	NULL
N.	NULL
,	NULL
A.	NULL
Bender	NULL
,	NULL
N.	NULL
Gonzalez	NULL
,	NULL
L.	NULL
Bui	NULL
,	NULL
M.	NULL
C.	NULL
Garrett	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1994	NULL
.	NULL

Influenza	NULL
virus-infected	NULL
dendritic	NULL
cells	NULL
stimulate	NULL
strong	NULL
proliferative	NULL
and	NULL
cytolytic	NULL
responses	NULL
from	NULL
human	NULL
CD8*	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

94:797	NULL
.	NULL

Bender	NULL
,	NULL
A.	NULL
,	NULL
L.	NULL
K.	NULL
Bui	NULL
,	NULL
M.	NULL
A.	NULL
V.	NULL
Feldman	NULL
,	NULL
M.	NULL
Larsson	NULL
,	NULL
and	NULL
N.	NULL
Bhardwaj	NULL
.	NULL

1995	NULL
.	NULL

Inactivated	NULL
influenza	NULL
virus	NULL
,	NULL
when	NULL
presented	NULL
on	NULL
dendritic	NULL
cells	NULL
,	NULL
elicits	NULL
human	NULL
CD8	NULL
cytolytic	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
182:1663	NULL
.	NULL

Sallusto	NULL
F.	NULL
,	NULL
M.	NULL
Cella	NULL
,	NULL
C.	NULL
Danieli	NULL
,	NULL
and	NULL
A.	NULL
Lanzauecchia	NULL
1995	NULL
.	NULL

Dendritic	NULL
cells	NULL
use	NULL
macropinocytosis	NULL
and	NULL
the	NULL
mannose	NULL
receptor	NULL
to	NULL
concentrate	NULL
macromolecules	NULL
in	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
compartment	NULL
:	NULL
downregulation	NULL
by	NULL
cy-tokines	NULL
and	NULL
bacterial	NULL
products	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:389	NULL
.	NULL

Zhu	NULL
,	NULL
Z.	NULL
,	NULL
M.	NULL
D.	NULL
Gershon	NULL
,	NULL
R.	NULL
Ambron	NULL
,	NULL
C.	NULL
Gabel	NULL
,	NULL
and	NULL
A	NULL
.	NULL

A.	NULL
Gershon	NULL
.	NULL

1994	NULL
.	NULL

Infection	NULL
of	NULL
cells	NULL
by	NULL
varicella	NULL
zoster	NULL
virus	NULL
:	NULL
inhibition	NULL
of	NULL
viral	NULL
entry	NULL
by	NULL
mannose	NULL
6-phos-phate	NULL
and	NULL
heparin	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
92:3546	NULL
.	NULL

Fagnoni	NULL
,	NULL
F.	NULL
F.	NULL
,	NULL
M.	NULL
Takamizawa	NULL
,	NULL
W.	NULL
R.	NULL
Godfrey	NULL
,	NULL
A.	NULL
Rivas	NULL
,	NULL
M.	NULL
Azuma	NULL
,	NULL
K.	NULL
Okumura	NULL
,	NULL
and	NULL
E.	NULL
G.	NULL
Engleman	NULL
.	NULL

1995	NULL
.	NULL

Role	NULL
of	NULL
B70/B7-2	NULL
in	NULL
CD4*	NULL
T-cell	NULL
immune	NULL
responses	NULL
induced	NULL
by	NULL
dendritic	NULL
cells	NULL
.	NULL

Immunology	NULL
85:467	NULL
.	NULL

Caux	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
Massacrier	NULL
,	NULL
C.	NULL
Dezutter-Dambuyant	NULL
,	NULL
B.	NULL
Vanberviet	NULL
,	NULL
C.	NULL
Jacquet	NULL
,	NULL
D.	NULL
Schmitt	NULL
,	NULL
and	NULL
J.	NULL
Banchereau	NULL
.	NULL

1995	NULL
.	NULL

Human	NULL
dendritic	NULL
Langerhans	NULL
cells	NULL
generated	NULL
in	NULL
vitro	NULL
from	NULL
CD34*	NULL
progenitors	NULL
can	NULL
prime	NULL
naive	NULL
CD4*	NULL
T	NULL
cells	NULL
and	NULL
process	NULL
soluble	NULL
antigen	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:5427	NULL
.	NULL

Constant	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
Sant	NULL
'	NULL
Angelo	NULL
,	NULL
T.	NULL
Pasqualini	NULL
,	NULL
T.	NULL
Taylor	NULL
,	NULL
D.	NULL
Levin	NULL
,	NULL
R.	NULL
Flavell	NULL
,	NULL
and	NULL
K.	NULL
Bottomly	NULL
.	NULL

1995	NULL
.	NULL

Peptide	NULL
and	NULL
protein	NULL
antigens	NULL
require	NULL
distinct	NULL
antigen-presenting	NULL
cell	NULL
subsets	NULL
for	NULL
the	NULL
priming	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

155:4915	NULL
.	NULL

Rescigno	NULL
,	NULL
M.	NULL
,	NULL
C.	NULL
Winzler	NULL
,	NULL
D.	NULL
Delia	NULL
,	NULL
C.	NULL
Mutini	NULL
,	NULL
M.	NULL
Lutz	NULL
,	NULL
and	NULL
P.	NULL
Ricciardi-Castagnoli	NULL
.	NULL

1997	NULL
.	NULL

Dendritic	NULL
cell	NULL
maturation	NULL
is	NULL
required	NULL
for	NULL
initiation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

J.	NULL
Leukocyte	NULL
Biol	NULL
.	NULL

61:415	NULL
.	NULL

Kinchington	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
J.	NULL
K.	NULL
Houghland	NULL
,	NULL
A.	NULL
M.	NULL
Arvin	NULL
,	NULL
W.	NULL
T.	NULL
Ruyechan	NULL
,	NULL
and	NULL
J.	NULL
Hay	NULL
.	NULL

1992	NULL
Varicella	NULL
zoster	NULL
virus	NULL
IE62	NULL
protein	NULL
is	NULL
a	NULL
major	NULL
virion	NULL
component	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:359	NULL
.	NULL

Bergen	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
P.	NULL
S.	NULL
Diaz	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Arvin	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
immunogenicity	NULL
of	NULL
the	NULL
Oka/Merck	NULL
varicella	NULL
vaccine	NULL
in	NULL
relation	NULL
to	NULL
infectious	NULL
varicella-zoster	NULL
virus	NULL
and	NULL
relative	NULL
viral	NULL
antigen	NULL
content	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

162:1049	NULL
.	NULL

Bergen	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
M.	NULL
Sharp	NULL
,	NULL
A.	NULL
Sanchez	NULL
,	NULL
A.	NULL
K.	NULL
Judd	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Arvin	NULL
.	NULL

1991	NULL
.	NULL

Human	NULL
T	NULL
Cells	NULL
recognize	NULL
multiple	NULL
eptiopes	NULL
of	NULL
a	NULL
major	NULL
tegument/immediate	NULL
early	NULL
protein	NULL
(	NULL
IE62	NULL
)	NULL
and	NULL
glycoprotein	NULL
I	NULL
of	NULL
varicella-zoster	NULL
virus	NULL
.	NULL

Viral	NULL
Immunol	NULL
.	NULL

4:151	NULL
.	NULL

Centers	NULL
for	NULL
Disease	NULL
Control	NULL
.	NULL

1996	NULL
.	NULL

Prevention	NULL
of	NULL
varicella	NULL
:	NULL
recommendations	NULL
of	NULL
the	NULL
Advisory	NULL
Committee	NULL
on	NULL
Immunization	NULL
Practices	NULL
.	NULL

Morbid	NULL
.	NULL

Mortal	NULL
.	NULL

Wkly	NULL
.	NULL

Rep.	NULL
45:1	NULL
.	NULL

Margalit	NULL
H.	NULL
,	NULL
J.	NULL
L.	NULL
Spouge	NULL
,	NULL
J.	NULL
L.	NULL
Cornette	NULL
,	NULL
K.	NULL
B	NULL
.	NULL

Cease	NULL
,	NULL
C.	NULL
Delisi	NULL
,	NULL
and	NULL
J.	NULL
A.Ber-zofsky	NULL
.	NULL

1987	NULL
.	NULL

Prediction	NULL
of	NULL
immunodominant	NULL
helper	NULL
T	NULL
cell	NULL
antigenic	NULL
sites	NULL
from	NULL
the	NULL
primary	NULL
sequence	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

138:2213	NULL
.	NULL

Rothbard	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
W.	NULL
R.	NULL
Taylor	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
sequence	NULL
pattern	NULL
common	NULL
to	NULL
T	NULL
cell	NULL
epitopes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

7:93	NULL
.	NULL

Clarke	NULL
,	NULL
P.	NULL
,	NULL
A.	NULL
Brunschwig	NULL
,	NULL
and	NULL
D.	NULL
H.	NULL
Gilden	NULL
.	NULL

1997	NULL
.	NULL

DNA	NULL
sequence	NULL
of	NULL
a	NULL
simian	NULL
varicella	NULL
virus	NULL
gene	NULL
that	NULL
encodes	NULL
a	NULL
homologue	NULL
of	NULL
varicella	NULL
zoster	NULL
virus	NULL
IE62	NULL
and	NULL
herpes	NULL
simplex	NULL
virus	NULL
.	NULL

Virology	NULL
1:45	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

567	NULL
Gray	NULL
,	NULL
W.	NULL
L.	NULL
,	NULL
N.	NULL
J.	NULL
Gusick	NULL
,	NULL
C.	NULL
Ek-Kommonen	NULL
,	NULL
S.	NULL
E.	NULL
Kempson	NULL
,	NULL
and	NULL
T.	NULL
M.	NULL
Fletcher	NULL
III	NULL
1995	NULL
.	NULL

The	NULL
inverted	NULL
repeat	NULL
regions	NULL
of	NULL
the	NULL
simian	NULL
varicella	NULL
virus	NULL
and	NULL
varicella-zoster	NULL
virus	NULL
genomes	NULL
have	NULL
a	NULL
similar	NULL
genetic	NULL
organization	NULL
.	NULL

Virus	NULL
Res	NULL
.	NULL

39:181	NULL
.	NULL

Schuler	NULL
,	NULL
G.	NULL
,	NULL
B.	NULL
Thurner	NULL
,	NULL
and	NULL
N.	NULL
Romani	NULL
.	NULL

1997	NULL
.	NULL

Dendritic	NULL
cells	NULL
:	NULL
from	NULL
ignored	NULL
cells	NULL
to	NULL
major	NULL
players	NULL
in	NULL
T-cell-mediated	NULL
immunity	NULL
.	NULL

Int	NULL
.	NULL

Arch	NULL
.	NULL

Allergy	NULL
Immunol	NULL
.	NULL

112	NULL
:	NULL
317	NULL
.	NULL

Manca	NULL
,	NULL
F.	NULL
,	NULL
G.	NULL
Li	NULL
Pira	NULL
,	NULL
D.	NULL
Fenoglio	NULL
,	NULL
S.	NULL
P.	NULL
Fang	NULL
,	NULL
A.	NULL
Habeshaw	NULL
,	NULL
S.	NULL
C.	NULL
Knight	NULL
,	NULL
and	NULL
A.	NULL
G.	NULL
Dalgleish	NULL
.	NULL

1994	NULL
.	NULL

Dendritic	NULL
cells	NULL
are	NULL
potent	NULL
antigen-presenting	NULL
cells	NULL
for	NULL
in	NULL
vitro	NULL
induction	NULL
of	NULL
primary	NULL
human	NULL
CD4*	NULL
T-cell	NULL
lines	NULL
specific	NULL
for	NULL
HIV	NULL
gp120	NULL
.	NULL

J	NULL
.	NULL

Acquired	NULL
Immune	NULL
Defic	NULL
.	NULL

Syndr	NULL
.	NULL

7:15	NULL
.	NULL

Chicz	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
R.	NULL
G.	NULL
Urban	NULL
,	NULL
J.	NULL
C.	NULL
Gorga	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

A.	NULL
Vignali	NULL
,	NULL
W.	NULL
S.	NULL
Lane	NULL
,	NULL
and	NULL
J.	NULL
L.	NULL
Strominger	NULL
.	NULL

1993	NULL
.	NULL

Specificity	NULL
and	NULL
promiscuity	NULL
among	NULL
naturally	NULL
processed	NULL
peptides	NULL
bound	NULL
to	NULL
HLA-DR	NULL
alleles	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:27	NULL
.	NULL

Quaki	NULL
,	NULL
I	NULL
.	NULL

A.	NULL
,	NULL
J.	NULL
Currier	NULL
,	NULL
A	NULL
.	NULL

Fell	NULL
,	NULL
D.	NULL
W.	NULL
Taylor	NULL
,	NULL
T.	NULL
Roberts	NULL
,	NULL
R.	NULL
A.	NULL
Houghten	NULL
,	NULL
R.	NULL
D.	NULL
England	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Berzofsky	NULL
,	NULL
L.	NULL
H.	NULL
Miller	NULL
,	NULL
and	NULL
M.	NULL
F.	NULL
Good	NULL
.	NULL

1994	NULL
.	NULL

Analysis	NULL
of	NULL
human	NULL
T	NULL
cell	NULL
clones	NULL
specific	NULL
for	NULL
conserved	NULL
peptide	NULL
sequences	NULL
within	NULL
malaria	NULL
proteins	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:2082	NULL
.	NULL

Caux	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
Massacrier	NULL
,	NULL
B.	NULL
Vanbervliet	NULL
,	NULL
B.	NULL
Dubois	NULL
,	NULL
C.	NULL
Van	NULL
Kooten	NULL
,	NULL
I.	NULL
Durand	NULL
,	NULL
and	NULL
J.	NULL
Banchereau	NULL
.	NULL

1994	NULL
.	NULL

Activation	NULL
of	NULL
human	NULL
dendritic	NULL
cells	NULL
through	NULL
CD40	NULL
cross-linking	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1263	NULL
.	NULL

Cella	NULL
M.	NULL
,	NULL
D.	NULL
Scheidegger	NULL
,	NULL
K.	NULL
Palmer-Lehmann	NULL
,	NULL
P.	NULL
Lane	NULL
,	NULL
A.	NULL
Lanzavecchia	NULL
,	NULL
and	NULL
G.	NULL
Alber	NULL
.	NULL

1996	NULL
.	NULL

Ligation	NULL
of	NULL
CD40	NULL
on	NULL
dendritic	NULL
cells	NULL
triggers	NULL
production	NULL
of	NULL
high	NULL
levels	NULL
of	NULL
interleukin-12	NULL
and	NULL
enhances	NULL
T	NULL
cell	NULL
stimulatory	NULL
capacity	NULL
:	NULL
T-T	NULL
help	NULL
via	NULL
APC	NULL
activation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:747	NULL
.	NULL

Jenkins	NULL
,	NULL
D.	NULL
E.	NULL
,	NULL
R.	NULL
L.	NULL
Redman	NULL
,	NULL
E.	NULL
M.	NULL
Lam	NULL
,	NULL
C.	NULL
Liu	NULL
,	NULL
I.	NULL
Lin	NULL
,	NULL
and	NULL
A.	NULL
M.	NULL
Arvin	NULL
.	NULL

1998	NULL
.	NULL

TL-10	NULL
,	NULL
IL-12	NULL
and	NULL
IFN-y	NULL
production	NULL
in	NULL
primary	NULL
and	NULL
memory	NULL
immune	NULL
responses	NULL
to	NULL
varicella-zoster	NULL
virus	NULL
.	NULL

J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

178:940	NULL
.	NULL

O'Doherty	NULL
,	NULL
U.	NULL
,	NULL
R.	NULL
M.	NULL
Steinman	NULL
,	NULL
M.	NULL
Peng	NULL
,	NULL
P.	NULL
U.	NULL
Cameron	NULL
,	NULL
S.	NULL
Gezelter	NULL
,	NULL
I.	NULL
Kopeloff	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Swiggard	NULL
.	NULL

1993	NULL
.	NULL

Dendritic	NULL
cells	NULL
freshly	NULL
isolated	NULL
from	NULL
human	NULL
blood	NULL
express	NULL
CD4	NULL
and	NULL
mature	NULL
into	NULL
typical	NULL
immunostimulatory	NULL
dendritic	NULL
cells	NULL
after	NULL
culture	NULL
in	NULL
monocyte-conditioned	NULL
medium	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:1067	NULL
.	NULL

Sipsas	NULL
,	NULL
N.	NULL
V.	NULL
,	NULL
S.	NULL
A.	NULL
Kalams	NULL
,	NULL
A.	NULL
Trocha	NULL
,	NULL
S.	NULL
He	NULL
,	NULL
W.	NULL
A.	NULL
Blattner	NULL
,	NULL
B.	NULL
D.	NULL
Walker	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Johnson	NULL
.	NULL

1997	NULL
.	NULL

Identification	NULL
of	NULL
type-specific	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
responses	NULL
to	NULL
homologous	NULL
viral	NULL
proteins	NULL
in	NULL
laboratory	NULL
workers	NULL
accidentally	NULL
infected	NULL
with	NULL
HIV-1	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

99:752	NULL
.	NULL

Gelder	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
J.	NULL
R.	NULL
Lamb	NULL
,	NULL
and	NULL
B	NULL
.	NULL

A.	NULL
Askonas	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
CD4*	NULL
T	NULL
cell	NULL
recognition	NULL
of	NULL
influenza	NULL
A	NULL
virus	NULL
hemagglutinin	NULL
after	NULL
subunit	NULL
vaccination	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:4784	NULL
.	NULL

Moulon	NULL
,	NULL
C.	NULL
,	NULL
J.	NULL
Peguet-Navarro	NULL
,	NULL
P.	NULL
Courtellemont	NULL
,	NULL
G.	NULL
Redziniak	NULL
,	NULL
and	NULL
D.	NULL
Schmitt	NULL
.	NULL

1993	NULL
.	NULL

In	NULL
vitro	NULL
primary	NULL
sensitization	NULL
and	NULL
restimulation	NULL
of	NULL
hapten-specific	NULL
T	NULL
cells	NULL
by	NULL
fresh	NULL
and	NULL
cultured	NULL
human	NULL
epidermal	NULL
Langethans	NULL
'	NULL
cells	NULL
.	NULL

Immunology	NULL
80:373	NULL
.	NULL

Hickman	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
A.	NULL
S.	NULL
Khan	NULL
,	NULL
P.	NULL
A.	NULL
Rota	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Bellini	NULL
.	NULL

1997	NULL
.	NULL

Use	NULL
of	NULL
synthetic	NULL
peptides	NULL
to	NULL
identify	NULL
measles	NULL
nucleoprotein	NULL
T-cell	NULL
epitopes	NULL
in	NULL
vaccinated	NULL
and	NULL
naturally	NULL
infected	NULL
humans	NULL
.	NULL

Virology	NULL
235:386	NULL
.	NULL

Aron	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Horwitz	NULL
.	NULL

1992	NULL
.	NULL

Synthetic	NULL
peptides	NULL
as	NULL
vaccines	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

4:449	NULL
.	NULL

Obeid	NULL
,	NULL
O.	NULL
E.	NULL
,	NULL
C.	NULL
D.	NULL
Partidos	NULL
,	NULL
C.	NULL
R.	NULL
Howard	NULL
,	NULL
and	NULL
M.	NULL
W.	NULL
Steward	NULL
.	NULL

1995	NULL
.	NULL

Protection	NULL
against	NULL
morbillivirus-induced	NULL
encephalitis	NULL
by	NULL
immunization	NULL
with	NULL
a	NULL
rationally	NULL
designed	NULL
synthetic	NULL
peptide	NULL
vaccine	NULL
containing	NULL
B-	NULL
and	NULL
T-cell	NULL
epitopes	NULL
from	NULL
the	NULL
fusion	NULL
protein	NULL
of	NULL
measles	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:1420	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL

